Document:

Amended and Restated Supply Agreement

 Exhibit 10.1 
 AMENDED AND RESTATED SUPPLY AGREEMENT 
 THIS AMENDED AND RESTATED SUPPLY AGREEMENT (the “Agreement”) is entered into this 25th day of May, 2007 (the
“Effective Date”) by and between PLANTEX USA, Inc., a corporation organized under the laws of the State of New Jersey with offices at 2 University Plaza, Suite 305, Hackensack, New Jersey 07601 (“PLANTEX”) and
NOVACEA, Inc. (formerly known as D-Novo Therapeutics, Inc.) a corporation organized under the laws of the State of Delaware with offices at 601 Gateway Blvd., Suite 800, South San Francisco, Ca 94080 (“NOVACEA”) and hereby amends
and restates that certain Supply Agreement as amended on or about January 24, 2006, March 21, 2006 and March 13, 2007 (the “Original Agreement”) entered into between the parties effective as of 27th day of December, 2001 (the “Original Effective Date”). 
 WITNESSETH 
 WHEREAS, the parties have entered into the Original
Agreement pursuant to which PLANTEX (or an Affiliate thereof) will supply NOVACEA Active Pharmaceutical Ingredients, or API, (as defined below) for the Finished Product (as defined below) and NOVACEA (including Affiliates thereof and their
respective licensees and contract manufacturing vendors, if any) will purchase from PLANTEX requirements as set forth below, of API used in the manufacture of Finished Product; and 
 WHEREAS, this Agreement is an amendment and restatement of the Original Agreement, and completely supersedes and replaces the Original Agreement.

 NOW, THEREFORE, in consideration of the premises and of the mutual covenants and agreements set forth in this Agreement, the parties agree
as follows: 
  

	1.	DEFINITIONS  

 The following words and phrases
shall, for purposes of this Agreement, have the following meanings (with any term or phrase referred to below, or defined elsewhere in this Agreement, in the singular to include the plural and vice versa as the context requires): 
 “Action” shall mean any suit, action, investigation (governmental or otherwise), claim or proceeding initiated or filed against a party
to this Agreement, which results in or could result in a Loss or Losses for which indemnification is required by the other party under Article 13 below. 
 “Active Pharmaceutical Ingredients” or “API” shall mean bulk, unformulated Calcitriol. 
 “Affiliate” of any party shall mean any Person that is controlled by, controls, or is under common control with such party. For this purpose, “control” of a corporation or other
business entity shall mean the direct or indirect beneficial ownership of more than fifty percent (50%) in the equity of, or the right to appoint more than fifty (50) percent of the directors or management of such corporation or other
business entity. 

 “Agreement” shall mean this Agreement as it is amended from time to time in the manner
provided herein. 
 “ANDA” shall mean an Abbreviated New Drug Application filed with the FDA pursuant to its rules and
regulations. 
 “Approval” shall mean any and all approvals, licenses, registrations or authorizations of the applicable
Regulatory Authority necessary for the marketing of Finished Products in the relevant country in the Territory. 
 “cGMP”
shall mean current good manufacturing practices as set forth in regulations issued by the FDA from time to time. 
 “Commercialization Partner” shall mean a commercial entity with global annual human pharmaceutical gross revenues of at least [*] dollars ($[*]). 
 “Contract Year” shall mean the twelve (12) month period measured from a specific date or event. 
 “DMFs” shall mean the drug master files covering the analysis and manufacture of the API, comprising any and all technical information
in the possession of PLANTEX (or an Affiliate thereof), including, without limitation, analytical methods, stability and pharmaceutical data, impurities, and manufacturing processes with respect to the API. 
 “Effective Date” shall mean May 25, 2007. 
 “Finished Products” or “Finished Product” shall mean such pharmaceutical products developed and/or marketed by NOVACEA for the treatment and/or prevention of any cancer containing API
as shall receive Approval for marketing by a Regulatory Authority. 
 “FDA” shall mean the United States Food and Drug
Administration and all agencies under its direct control or any successor organization. 
 “FFDCA” shall mean the Federal
Food, Drug and Cosmetic Act of 1934, as amended from time to time, and the regulations promulgated pursuant thereto, or any successor statute adopted to replace such act. 
 “Indemnified Party” shall mean the party to this Agreement entitled to be indemnified by the Indemnifying Party against a Loss or Losses pursuant to Article 13 below. 
 “Initial Launch” means the date on which NOVACEA (or any of its Affiliates or their respective licensees, if any) makes its first
commercial sale in the Territory of any Finished Product to an unaffiliated third party. 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 -2- 

 “Loss” or “Losses” shall mean any liability, loss, costs, damage or
expense, including reasonable attorneys’ fees and expenses, incurred or suffered by a party to this Agreement, except for consequential damages, for which indemnification is required under Article 13 below. 
 “Manufacture” and “manufacturing” and other forms of such word or phrase shall refer to the manufacturing, handling,
packaging, storage and/or disposal of the API and the raw materials and components used in connection therewith. 
 “NDA”
means a New Drug Application filed with the FDA pursuant to its rules and regulations. 
 “Original Agreement” means that certain Supply Agreement entered into between the parties effective as of 27th day of December,
2001 and as amended on or about January 24, 2006, March 21, 2006 and March 13, 2007. 
 “Original Effective Date” means 27th day of December, 2001. 
 “Party” or “Parties”, when referring to the parties to this Agreement shall mean and include PLANTEX and NOVACEA, or
each of them individually. 
 “Person” shall mean any individual, partnership, association, corporation, trust or legal
person or entity. 
 “Regulatory Authority” shall mean any and all governmental bodies, organizations and agencies whose
approval is necessary to develop, manufacture, import, use, and or market Finished Products in the relevant country of the Territory 
 “Territory” shall mean worldwide. 
  

	2.	TERM  

 The initial term of this Agreement shall begin on the Original Effective Date and unless terminated in the manner provided in Article 14 hereof, shall expire upon the expiration of the greater of (i) ten
(10) Contract Years from the Original Effective Date or (ii) the tenth (10th) anniversary of the date occurring prior to the tenth
anniversary of the Original Effective Date that NOVACEA receives marketing approval for Finished Product from the FDA (“Initial Term”). NOVACEA shall notify PLANTEX in writing within five (5) days following receipt of such
marketing approval. This Agreement shall be automatically extended upon the same terms and conditions for successive two (2) year periods (“Renewal Term”) unless either Party shall have provided notice of its intent not to
renew this Agreement not less than one (1) year prior to expiration of the Initial Term or any Renewal Term then in effect. For purposes of this Agreement “Term” shall refer collectively to the Initial Term and the Renewal
Terms, unless the context otherwise requires. 
  

	3.	SCOPE OF THE AGREEMENT  

 This Agreement shall apply
to purchases during the Term by NOVACEA (and its 

  

 -3- 

 
Affiliates and their respective licensees and contract manufacturing vendors, if any) of API and their respective, direct or indirect, successors and
permitted assigns, for the development, commercialization, distribution and sale of Finished Product in the Territory. 
  

	4.	DEVELOPMENT EFFORT  

 NOVACEA agrees at its sole
cost and expense to use its best efforts to obtain Approval to market Finished Product in such countries in the Territory as shall be reasonably determined by NOVACEA, except that NOVACEA shall use its best efforts to obtain FDA Approval to market
Finished Product in the United States based upon a NDA or ANDA, as shall be determined by NOVACEA. Notwithstanding the foregoing, if NOVACEA enters into an agreement with an effective date of no later than [*] with a Commercialization Partner to
commercialize the Finished Product, then the standard above shall not apply and instead the standard provided in NOVACEA’s agreement with such Commercialization Partner shall apply which will at least be a commercially reasonable efforts
standard. Alternatively, if this Agreement is assigned to such Commercialization Partner, then the standard applicable to the Commercialization Partner shall be the commercially reasonable efforts standard. In connection with the FDA Approval
described above, NOVACEA shall at its sole cost and expense conduct all tests and studies reasonably required to enable NOVACEA to apply for, obtain and maintain FDA Approval for Finished Product. In connection with the development of Finished
Product and securing any Approvals, NOVACEA agrees, on behalf of itself, its Affiliates and their respective licensees or contract manufacturing vendors, if any, to use only API obtained from PLANTEX (or its Affiliates) and from the second source
that NOVACEA proposes to utilize pursuant to Section 5.1 below, and purchase all their respective development requirements of API from PLANTEX (or its Affiliates) and such second source. Upon the execution and delivery of this Agreement,
PLANTEX shall provide and deliver to NOVACEA without charge two (2) grams of API. Thereafter, NOVACEA shall be charged [*] dollars ($[*]) per gram for Developmental Orders (as herein defined) of API sold hereunder and such price shall not be
subject to increase or decrease. Notwithstanding Section 6.2 below, such payment shall be due and payable upon delivery to NOVACEA of any Developmental Order or portion thereof. As used herein, “Developmental Orders” means
orders placed prior to Approval by a Regulatory Authority and not in connection with commercial production in connection with commercial launch following any such Approval. After January 1, 2008, all Developmental Orders shall be minimum
noncancellable orders for quantities of not less than [*] grams each, such quantities currently forecasted by NOVACEA at [*] grams for 2008, [*] grams for 2009 and [*] grams for 2010. For Developmental Orders on an annual basis after 2010, NOVACEA
shall notify PLANTEX of its minimum noncancellable quantities for the applicable year (not to be less than [*] grams each year) no later than September 30 of the preceding calendar year. Each of the Developmental Orders shall be deliverable
over periods not exceeding twelve (12) months, in partial shipments of not less than [*] grams each and not greater than [*] grams each; provided that PLANTEX shall use commercially reasonable efforts to deliver to NOVACEA or its designee
quantities set forth in a Developmental Order quarterly shipments of no less than [*] percent ([*]%) of the applicable Developmental Order. 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 -4- 

	5.	COMMERCIAL SUPPLY.  

 5.1 NOVACEA Purchases.
(i) NOVACEA covenants and agrees for and on behalf of itself, its Affiliates and their respective licensees and contract manufacturing vendors, if any, that each of them shall purchase from PLANTEX or its designated Affiliates at least [*]
percent of its annual requirements of API used by it in connection with its manufacture, sale and distribution of Finished Products within the Territory; provided, however, that NOVACEA together with any of its Affiliates, licensees or contract
manufacturing vendors, shall not in any calendar year purchase from any source other than PLANTEX or its designated Affiliates more than an amount sufficient to maintain qualification of a second source supplier (which amount shall be at least [*]
grams and no more than [*] grams of API), but may purchase up to such [*] gram amount, notwithstanding such [*] percent ([*]%) requirement, if such amount is necessary to keep a second manufacturing source qualified under Section 5.2 below. Any
license or contract manufacturing agreement for the benefit of NOVACEA or any of its Affiliates shall contain a provision requiring such licensee or contract manufacturer to purchase from PLANTEX or its designated Affiliate no less than [*] percent
of such party’s annual requirements of API for use in connection with the manufacture, sale or distribution of Finished Product in the Territory upon the terms and conditions applicable to purchases hereunder by NOVACEA, and barring such party
from purchasing from any source other than PLANTEX or its designated Affiliate any amount of API that would result in an aggregate purchase of more than an amount sufficient to maintain qualification of a second source supplier (which amount shall
be at least [*] grams and no more than [*] grams of API in any calendar year for use by NOVACEA, its Affiliates and their respective licensees and contract manufacturers, subject to the ability to purchase up to such amount, notwithstanding such [*]
percent ([*]%) requirement, if such amount is necessary to keep a second manufacturing source qualified for the purpose of Section 5.2 below. Any such license or contract manufacturing agreement shall make specific reference to this Agreement
and state with affirmative language that PLANTEX shall have the rights of a third party beneficiary with respect to such agreement. 
 (ii)
NOVACEA covenants that, to the extent that NOVACEA or its Affiliates or licensees or contract manufacturers elect to purchase from a source other than PLANTEX or its designated Affiliates any API for use in connection with its manufacture, sale and
distribution of Finished Products within the Territory, NOVACEA shall treat as confidential and not disclose to such source any PLANTEX Confidential Information (as defined in Section 16.1, below) including, without limitation, PLANTEX’s
product manufacturing procedures, levels of impurities, certified analytical standards and analytical methods, and shall cause its Affiliates, licensees and contract manufacturers to comply with this covenant. 
 (iii) Within sixty (60) days after the last day of each calendar year commencing the calendar year of first commercial sale of Finished Product in
the United States, NOVACEA shall certify to PLANTEX in writing that: (i) neither NOVACEA nor any Affiliate or licensee or contract manufacturing vendor of NOVACEA or its Affiliates has in such calendar year purchased from any source other than
PLANTEX or its designated Affiliates API for use in connection with the manufacture, sale or distribution of Finished Product in the Territory in excess of the amounts 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 -5- 

 
permitted in Section 5.1(i), above, and (ii) neither NOVACEA nor any of its Affiliates, licensees or contract manufacturing vendors has disclosed
to any third party any PLANTEX Confidential Information in violation of the covenant set forth in Section 5.1(ii), above. PLANTEX shall have the right, not more than once each calendar year, during normal business hours and on at least ten
(10) business days’ advance notice to NOVACEA, to inspect the books and records and facilities of NOVACEA and its Affiliates to confirm the accuracy of the certification made by NOVACEA pursuant to this Section 5.1(iii). 

(iv) Subject to Section 13.2 below, in the event that NOVACEA is in breach of either of its covenants set forth in Sections 5.1(i) and 5.1(ii),
above, then PLANTEX shall be entitled to seek all damages and other legal remedies resulting from such breach, including without limitation, the right to terminate this Agreement as provided in Section 14.1(ii), below. 
 5.2 Exception. During any period in which PLANTEX, for any reason, including but not limited to force majeure as provided for in Section 15,
fails to supply, is unable to supply or anticipates that it will be unable to supply, the quantities of API to NOVACEA included within any Firm Purchase Order (as defined below) or any other purchase order confirmed in writing by PLANTEX, NOVACEA
shall be free to fill such specific purchase order for API (or any unfilled portion) from an alternative source. This shall be the sole remedy for NOVACEA in the event that PLANTEX advises that it is unable to supply API. PLANTEX shall notify
NOVACEA promptly upon becoming aware of any facts or circumstances, which causes it to believe that it will be unable to meet shipment obligations hereunder. For clarity, notwithstanding any other term or provision of this Agreement, for purposes of
exercising NOVACEA’s rights under Section 5.1 to purchase up to [*] percent ([*]%) of its requirements from third parties and this Section 5.2 for failure to supply, NOVACEA may enter into discussions with potential alternative
sources and conduct any and all activities necessary (subject to Section 5.1(ii) to validate and qualify an alternative source as a suitable alternative source supplier, at any time during the term of this Agreement, so that a qualified
alternative source supplier will be available for the manufacture of API as permitted by Section 5.1 and this Section 5.2. 
 5.3
Sole Supply. PLANTEX shall not supply API to any other entity during the Term of this Agreement for use in the field of the treatment, diagnosis, and/or prevention of any cancer, except for a pharmaceutical product that in the reasonable
judgment of NOVACEA shall not be in direct competition with NOVACEA’s approved NDA Product, such determination to be made by NOVACEA promptly following the written request therefore by PLANTEX. 
 5.4 Specifications. PLANTEX shall provide with each shipment of API a certificate of analysis. PLANTEX (or an Affiliate thereof) shall file and
maintain a valid DMF for the API with the FDA, which is in full compliance with FDA requirements for DMFs. Provided that NOVACEA is not in material breach of its obligations hereunder, NOVACEA, its Affiliates, or licensees, shall have the right to
reference PLANTEX’s DMF for API in any drug application seeking Approval for Finished Product from a Regulatory Authority. All API shall be manufactured in accordance with cGMP and shall meet the specifications set forth in Schedule A
annexed to this Agreement. 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 -6- 

 5.5 Forecasts and Purchase Orders. [*] months prior to the date on which NOVACEA, in good faith,
anticipates Approval, NOVACEA will provide PLANTEX with [*] month rolling forecasts of its requirements by calendar quarter for API. Thereafter, such rolling forecasts shall be delivered to PLANTEX on or before the fifteenth (15th) day of each
calendar quarter during the Term. The first calendar quarter of each [*] month rolling forecast shall be binding on PLANTEX and NOVACEA and shall constitute a firm purchase order (“Firm Purchase Order”) for the API indicated for
such calendar quarter. PLANTEX shall supply NOVACEA with (i) the quantities set forth on each such Firm Purchase Order and (ii) such additional amounts as NOVACEA may order in excess of its forecasted amounts for such calendar quarter,
provided that PLANTEX shall have confirmed and accepted such additional orders within thirty (30) days of PLANTEX’s receipt of NOVACEA’s written request for such additional amounts. PLANTEX agrees to use commercially reasonable
efforts to meet any such additional orders. In the event that PLANTEX determines, based in part on NOVACEA’s good faith [*] month rolling forecast, on a consistent basis and in accordance with PLANTEX’s standard accounting practices, in
good faith (other than for reasons of force majeure as provided for in Section 15, below), that its revenues derived from manufacturing API are not equal to or exceed the costs for manufacture of API, and that it will therefore discontinue the
manufacture of API worldwide and terminate its delivery obligations to NOVACEA, and any other third party, by giving to NOVACEA not less than [*] months prior written notice, NOVACEA and/or its licensees shall have the right, within the first [*]
months of such [*] month period, to make a minimum [*] month purchase commitment in an amount sufficient to bring such revenues to a level equal to manufacturing costs plus [*] percent, in which case PLANTEX shall not be entitled to discontinue the
manufacture of API and terminate its delivery obligation hereunder, but will instead be obligated to continue the manufacture and delivery of API, as required by NOVACEA or its licensee. The terms and conditions of this Agreement shall apply to all
purchase orders hereunder and if any terms and conditions contained in such purchase orders shall conflict with any terms and conditions contained herein, the terms of this Agreement shall control. No additional terms or conditions set forth in any
such purchase order (other than the quantities and delivery dates set forth therein and conforming to the provisions of this Agreement) shall be binding upon PLANTEX, unless agreed to in writing by PLANTEX. Any additional terms therein contained
shall be deemed to be a proposed offer of amended terms that shall be deemed rejected by PLANTEX and of no force or effect, notwithstanding any action or inaction by PLANTEX other than its express written approval of such additional terms.

 5.6 Capacity. PLANTEX covenants to maintain capacity to manufacture on an annualized basis [*] percent of the forecasted
requirements of API set forth in any [*] month forecast submitted by NOVACEA in accordance with this Agreement, provided that the forecasted amount does not exceed the forecasted amount for the preceding year by [*] percent or more. Additionally,
following FDA Approval of Finished Product and continuing for the Term, PLANTEX shall maintain a six (6) month supply of API, based upon NOVACEA’s then-current forecasted amount. In order to further secure a supply of API hereunder,
PLANTEX shall develop a production contingency plan (which plan shall be presented to NOVACEA for its approval, which approval shall not be unreasonably withheld) designed to relocate the API site listed in the 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 -7- 

 
DMF for API or utilize an additional site in the event that PLANTEX makes a good faith determination that it is necessary to relocate such site or to utilize
an additional site in order to meet NOVACEA’s requirements of API. Such plan shall contemplate completion of relocation and securing necessary regulatory approvals within [*] of the determination by PLANTEX that such relocation was required. In
the event that relocation has not been completed within such [*] period, NOVACEA’s sole remedy shall be to terminate this Agreement. 
 5.7 Quality Agreement. Within ninety (90) days of the Effective Date, the parties shall execute a quality agreement (“Quality Agreement”), which sets out the responsibilities of the parties in connection with
the (i) API as they are related to quality control and quality assurance and (ii) the compliance with the European Union’s GMP regulation requiring the GMP status of the API manufacturer to be assured by the marketing authorization
holder or the final product manufacturer. In the event of a conflict between the terms of this Agreement and the Quality Agreement, this Agreement shall control. 
 5.8 Recordkeeping. NOVACEA shall keep and maintain or cause to be maintained books and records, pertaining to the use of API by NOVACEA and its Affiliates and their respective licensees or contract
manufacturing vendors, if any, in the manufacture, sale or distribution of Finished Products within the Territory, sufficient to enable PLANTEX to verify and confirm compliance by NOVACEA with the terms and conditions of this Agreement, including,
without limitation, the purchase of all requirements obligations in this Agreement. Such books and records shall be maintained in accordance with U.S. generally accepted accounting principles consistently applied. NOVACEA shall permit an independent
accounting firm selected by PLANTEX and acceptable to NOVACEA, at reasonable times and upon reasonable notice, to have access during normal business hours to the books and records of NOVACEA (and its Affiliates) as may be necessary to verify and
confirm compliance with the terms of this Section 5.8 with respect to use and inventory of API. The costs of any such examination shall be borne by PLANTEX unless it shall be determined that the quotient, q/r, expressed as a percentage, is less
than [*] percent, when (q) equals the aggregate quantities expressed in kilograms of API purchased from PLANTEX (or its Affiliates) by NOVACEA and its Affiliates, and their respective licensees or contract manufacturing vendors if any, for use
in the manufacture, sale or distribution of Finished Product in the Territory, and (r) equals the aggregate quantities expressed in kilograms of API purchased from all sources by NOVACEA and its Affiliates and their respective licensees and
contract manufacturing vendors, if any, for use in the manufacture, sale or distribution of Finished Product in the Territory, in which event NOVACEA shall reimburse PLANTEX all reasonable costs and expenses of such examination. PLANTEX shall keep
and maintain or cause to be maintained books and records pertaining to the manufacture of API for at least five (5) years or as required by law, whichever is longer. 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 -8- 

	6.	PRICE; PAYMENTS; DELIVERY  

 6.1 Price

 6.1.1 The price payable to PLANTEX hereunder for API shall be [*] dollars ($[*]) per gram. During development of the Finished Product,
PLANTEX agrees not to increase the price of API with respect to developmental quantities. At such time as NOVACEA receives FDA approval to market Finished Product, , provided that NOVACEA purchases not less than [*] grams of API in the first
Contract Year following Approval by a Regulatory Authority and in each Contract Year after the second anniversary of such Approval, the maximum price payable for API hereunder shall be [*] dollars ($[*]) per gram, except that such pricing may be
adjusted upwards for changes in the Consumer Price Index as follows: after the first anniversary of the Effective Date, prices charged following Approval by a Regulatory Authority in any Contract Year following the date hereof shall be determined by
multiplying the price of [*] dollars ($[*]) per gram by a fraction x/y, when (x) shall equal the Current Index (as herein defined) and (y) equals the Base Index (as herein defined). As used herein the Current Index shall be the Consumer
Price Index – All Urban Consumers (CPI-U), as published by the United States Department of Labor over the twelve (12) month period reported in such index immediately preceding the first day of each such Contract Year herein. The Base Index
shall be the Consumer Price Index – All Urban Consumers (CPI-U), as published by the United States Department of Labor for November 2001 (Base Index of 100). Commencing with the third anniversary of the Effective Date, once, during each
Contract Year thereafter, PLANTEX agrees to negotiate in good faith a price adjustment provided that NOVACEA can demonstrate that API is otherwise available, upon comparable terms and conditions as provided for herein, from an alternative supplier
(other than NOVACEA or any Affiliate thereof) holding an approved FDA DMF and offering such API at a price that is more than [*] percent below the price offered by PLANTEX herein. NOVACEA shall be relieved of the requirements purchase obligations
set forth in Section 5.1 of this Agreement and PLANTEX shall not be subject to the sole supply provisions set forth in Section 5.3 of this Agreement for such Contract Year or any subsequent Contract Year if, despite such good faith
negotiations, NOVACEA and PLANTEX are unable to reach a mutually satisfactory price within forty-five (45) days of the date on which NOVACEA notifies PLANTEX of such pricing availability. Nothing contained herein to the contrary shall require
PLANTEX to supply API at the pricing offered by any third party supplier. Additionally, PLANTEX and NOVACEA agree that they shall from time to time during the Term of this Agreement negotiate in good faith reductions in the price payable per gram
based on (i) NOVACEA purchases of quantities of API in excess of [*] grams in a Contract Year or (ii) a significant reduction in PLANTEX’s costs to manufacture API. Following the date of Initial Launch, PLANTEX shall give NOVACEA
prompt notice of any significant reduction in PLANTEX’s costs to manufacture API. Such reduction shall initially be determined based on PLANTEX’s costs to manufacture API as of the date of Initial Launch. PLANTEX’s costs to
manufacture API shall be determined from year to year on a consistent basis and in accordance with PLANTEX’s standard accounting practices. For purposes hereof, a “significant reduction” shall mean a reduction of [*] percent or
more, calculated on a cumulative basis (i.e., the reduction may occur over a period of greater than one (1) year). On each anniversary of the Effective Date, PLANTEX shall give NOVACEA notice of PLANTEX’s costs to manufacture API as of
such date. 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 -9- 

 6.1.2 The prices hereunder are F.O.B. PLANTEX’s facilities in New Jersey. 
 6.2 Payments  
 NOVACEA shall pay all
invoices net within thirty days (30) days of invoice date by bank wire transfer, by automated clearinghouse (electronic funds transfer) or by such other means as the parties may otherwise agree to in United States Dollars in the requisite
amount to such bank account as PLANTEX may from time to time designate. In the event that NOVACEA is delinquent in payment of invoices hereunder beyond the terms granted, PLANTEX, in its discretion, may suspend further shipments of API. Amounts not
paid when due shall accrue interest payable at the rate of twelve (12) percent per annum, not to exceed the maximum rate of interest permitted by law. Any such interest charges shall be due and payable on demand. 
 6.3 Delivery; Risk of Loss 
 Delivery
of all API sold by PLANTEX to NOVACEA hereunder shall be made, and title thereto and risk of loss thereof shall pass, to NOVACEA upon receipt of the API by NOVACEA at NOVACEA’s facility. 
  

	7.	INTENTIONALLY LEFT BLANK 

  

	8.	WARRANTIES; ACCEPTANCE AND CLAIMS 

 8.1 Limited
API Warranty. PLANTEX represents and warrants to NOVACEA that at the time of sale and delivery of API hereunder by PLANTEX, (i) the API manufactured and supplied will conform to the applicable specifications for API set forth on Schedule
A hereto, (ii) will have been manufactured, stored and packaged for shipment in accordance with cGMP in effect at the time thereof, and also in accordance with applicable laws, regulations and policies, including, but not limited to those
of the FDA, (iii) will not be adulterated or misbranded by PLANTEX or any other PLANTEX Affiliate within the meaning of the FFDCA, and (iv) will be free from defects. THE FOREGOING WARRANTY IS EXCLUSIVE AND IN LIEU OF ALL OTHER WARRANTIES
EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. 
 8.2
Notification of Defects. All API shall be received subject to NOVACEA’s inspection and may be rejected if any such API fails to be delivered in the condition warranted. NOVACEA shall be deemed to have accepted each order of API if
PLANTEX does not receive written notice to the contrary as set forth in this Section 8.2. NOVACEA shall notify PLANTEX in writing within forty-five (45) working days after delivery to NOVACEA of any non-conforming API containing obvious
defects discoverable without affecting the integrity of the APl’s packaging and will notify PLANTEX of nonconformity within thirty (30) working days from its discovery at any time of any latent defects, or NOVACEA’s rights as to such
obvious or latent non-conformance shall be waived. At PLANTEX’s request, NOVACEA shall promptly 

  

 -10- 

 
supply either samples of the API that are allegedly defective or some other evidence of deficiency that PLANTEX shall specify. If there is a disagreement
between the Parties as to whether any API conforms to specifications, or meets the warranties set forth in Section 8.1 above, then samples and/or batch records, as appropriate, from the batch that is in dispute promptly will be submitted for
testing and evaluation to an independent testing laboratory as shall be agreed to in writing by both Parties. The determination of such independent testing laboratory shall be binding upon the parties. If it is determined that the nonconformity is
due to damage to API (a) caused by NOVACEA or its agents or (b) which occurs subsequent to delivery of such API to NOVACEA, PLANTEX shall have no liability to NOVACEA with respect to such nonconformity and the cost of any testing and
evaluation by such testing laboratory shall be borne by NOVACEA. If it is determined that the nonconformity was not the result of either (a) or (b) above, then PLANTEX shall credit NOVACEA’s account for the price invoiced for such
nonconforming API (or if payment therefor has previously been made by NOVACEA, pay NOVACEA the amount of such credit or offset the amount thereof against other amounts then due to PLANTEX. 
 8.3 Notification. PLANTEX shall notify NOVACEA immediately in the event it discovers facts or circumstances that could adversely affect the
APl’s conformance to specifications or that would cause PLANTEX not to meet any of its warranties with respect to the API. 
 8.4
Returns. PLANTEX shall accept for return and replacement any API manufactured and supplied to NOVACEA under this Agreement which does not conform with any warranty set forth above and for which proper notice has been given, provided NOVACEA
obtains prior shipping authorization from PLANTEX. This shall be NOVACEA’s sole remedy for claims that any API failed to comply with the warranties provided in Section 8.1 herein. All returns of API with obvious defects shall be in the
original manufactured condition. PLANTEX will pay reasonable return freight and shipping charges, but NOVACEA shall assume the risk of loss in transit associated with such returns. 
  

	9.	DEBARMENT  

 Each party represents and warrants to
the other that neither it nor any of its officers, directors, or employees performing services under this Agreement has been debarred, or convicted of a crime which could lead to debarment, under the Generic Drug Enforcement Act of 1992, 21 United
States Code Sec. 306 (a) and (b). In the event that either party, or any of its officers, directors, or employees performing services under this Agreement, (a) becomes debarred or receives notice of action or threat of action with respect
to its debarment or (b) becomes the object of any investigation or subject of any report regarding such party, or any of its officers, directors, or employees performing services under this Agreement, in connection with any activity that could
result in debarment or suspension or refusal of approval, including without limitation any inspection report, warning letter, notice of opportunity for hearing in a case of debarment, or any other Justice Department, FDA or other federal or state
government inquiry or action bearing on potentially illegal activities, such party shall notify the other party immediately. 
  

 -11- 

	10.	FDA INSPECTIONS AND COMMUNICATIONS 

 PLANTEX shall
promptly notify NOVACEA of any FDA notices of violation or deficiency letters relating to the API. Each party shall promptly deliver to the other party all reports, data information and correspondence received by it from the FDA or any state or
local authority with respect to the API (or Finished Product) and any cGMP issues relating thereto and any written response information, data or correspondence delivered by such party to the FDA at any state or local authority with respect to the
API and shall cooperate to the extent reasonably requested by such other party in its response to the FDA or such other state or local authority. 
  

	11.	COMPLAINT HANDLING ADVERSE DRUG REACTION REPORTS 

 11.1 Complaint Handling. Except as otherwise provided below in Section 11.2, in the event that PLANTEX or NOVACEA receives any complaint, claims or adverse reaction reports regarding Finished Product, including notices from the
FDA regarding any alleged regulatory non-compliance of the Finished Product, each party shall, within five (5) business days, provide the other with all information contained in the complaint, report, or notice and such additional information
regarding the Finished Product as may be reasonably requested, except that notification by NOVACEA to PLANTEX shall be required only in those instances where any such complaint, claim or adverse reaction report appears to be related to API or where
in the exercise of reasonable judgment NOVACEA concludes or should conclude that such report contains information that may bear upon or relate to the possibility of prospective liability on the part of PLANTEX (or any Affiliate thereof). NOVACEA and
PLANTEX shall comply, at a minimum, with FDA and cGMP requirements for complaint handling. 
 11.2 Adverse Drug Reaction Reports.
NOVACEA shall maintain a system for monitoring, investigating and following up on adverse reaction reports received by it involving the Finished Product. If either party becomes aware that the Finished Product contains a defect which could or did
cause death or injury, each party shall immediately by FAX and telephone provide the other with a complete (where required by law) description of all relevant details known to such party concerning any such incident, including but not limited to, a
description of any defect and such other information which may be necessary to report the incident to the FDA, except that notification by NOVACEA to PLANTEX shall be required only in those instances where such defect relates to or appears to relate
to the API. NOVACEA will be responsible for preparing adverse drug reaction reports, administering adverse drug reaction files relating to the API and filing all such reports with FDA, at its sole expense. 
  

	12.	ACCESS TO FACILITIES AND AUDIT RIGHTS 

 12.1 Upon
reasonable notice, NOVACEA shall have the right, exercisable upon prior written notice no more frequently than on an annual basis, during normal business hours, with a maximum of two (2) persons, to inspect those areas of the facilities where
API is manufactured for NOVACEA (or its Affiliates) and to review the pertinent records relating to the manufacturing, packaging and quality control of the API. 
 12.2 PLANTEX agrees to keep full, clear and accurate books and records with respect 

  

 -12- 

 
to costs of commercial manufacture of API for a minimum period of three (3) years after the relevant cost determination is made pursuant to
Section 5.5. PLANTEX further agrees, upon reasonable prior notice, to permit such books and records to be examined during normal business hours by an independent nationally recognized accounting firm selected by NOVACEA and reasonably
acceptable to the PLANTEX for the purpose of verifying the cost plus [*] percent price under Section 5.5. Such audit shall not be performed more frequently than once per calendar year nor more frequently than once with respect to records
covering any specific period of time and shall be conducted under appropriate confidentiality provisions, for the sole purpose of verifying the accuracy and completeness of the financial, accounting and numerical information and calculations
provided in Section 5.5. Such examination is to be made at the expense of NOVACEA, except in the event that the results of the audit reveal an overpayment of for API of [*] percent ([*]%) or more over the period being audited, in which case
reasonable audit fees for such examination shall be paid by PLANTEX. 
  

	13.	INDEMNIFICATION 

 13.1
Indemnification. PLANTEX shall indemnify, defend, save and hold NOVACEA and each of its Affiliates, officers, directors, employees and agents harmless from and against Loss or Losses resulting from, or arising out of any material breach of
any warranty or material non-fulfillment or non-performance by PLANTEX of any agreement, covenant or obligation of PLANTEX under this Agreement. PLANTEX shall not be liable hereunder for any Loss or Losses resulting from any settlement of any claim,
litigation or proceeding effected without its consent, which consent shall not be unreasonably withheld.  
 NOVACEA shall indemnify,
defend, save and hold PLANTEX and each of its Affiliate, officers directors, employees and agents harmless from and against Loss or Losses resulting from, or arising out of (a) any material breach of any warranty or material non-fulfillment or
non-performance by NOVACEA of any agreement, covenant or obligation of NOVACEA contained in this Agreement; (b) any actual or alleged defect in any Finished Product sold by NOVACEA or any of its Affiliates or their respective licensees, if any,
not resulting from a material breach of this Agreement by PLANTEX; (c) any alleged infringement or violation of any patent, trade secret or proprietary rights used by NOVACEA or any of its Affiliates or their respective licensees or contract
manufacturing vendors, if any, in manufacturing, importing or selling of Finished Product, or (d) FDA enforcement action, inspection or Finished Product recalls or market withdrawals resulting from NOVACEA’s or any of its Affiliates or
their respective licenses or contract manufacturing vendors, if any, failure to manufacture Finished Product in accordance with all applicable laws, rules, orders or regulations. 
 13.2 Limitation of Liability. IN NO EVENT SHALL ANY PARTY BE LIABLE TO THE OTHER UNDER ANY PROVISION OF THIS AGREEMENT OR UNDER ANY CONTRACT,
NEGLIGENCE, STRICT LIABILITY OR OTHER LEGAL OR EQUITABLE THEORY FOR ANY RESULTANT, INDIRECT, SPECIAL OR EXEMPLARY DAMAGES OR, SPECIFICALLY, CONSEQUENTIAL DAMAGES OR DAMAGE TO GOODWILL AND REPUTATION. 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 -13- 

 13.3 Survival. The terms and conditions of Section 13 shall survive any termination of this
Agreement. 
 13.4 Indemnification Procedures. Upon the occurrence of an event that requires indemnification under this Agreement, the
Indemnified Party shall give prompt written notice to the Indemnifying Party providing reasonable details of the nature of the event and basis of the indemnity claim. The Indemnifying Party shall then have the right, at its expense and with counsel
of its choice, to defend, contest, or otherwise protect against any such Action. The Indemnified Party shall also have the right, but not the obligation, to participate, at its own expense in the defense thereof with counsel of its choice. The
Indemnified Party shall cooperate to the extent reasonably necessary to assist the Indemnifying Party in defending, contesting or otherwise protesting against any such Action provided that the Indemnifying Party shall pay the reasonable cost in
doing so. If the Indemnifying Party fails within thirty (30) days after receipt of such notice (a) to notify the Indemnified Party of its intent to defend, or (b) to defend, contest or otherwise protect against such suit, action,
investigation, claim or proceeding or fails to diligently continue to provide such defense after undertaking to do so, the Indemnified Party shall have the right upon ten (10) days prior written notice to the Indemnifying Party to defend,
settle and satisfy any such suit, action claim, investigation or proceeding and recover the costs of the same from the Indemnifying Party. 
  

	14.	TERMINATION 

 14.1 Termination. This
Agreement shall terminate upon the occurrence of any of the following events or conditions which termination shall automatically occur where termination by a specified party is not indicated and shall occur by action of the specified party where so
indicated: 
 (i) The expiration of the Initial Term or any Renewal Term; 
 (ii) The breach by either party of any provision of this Agreement which is not cured within thirty (30) days from the date of written notice
delivered to the defaulting party in the case of a payment default, and within ninety (90) days from the date of such notice in all other cases, unless such breach, not involving the payment of money, is of a nature that cannot be cured within
such ninety (90) day period and the breaching Party initiates the cure of such breach and proceeds diligently to remedy same provided, however, that only the aggrieved party can terminate this Agreement pursuant to this subsection (ii);

 (iii) The mutual written agreement of the parties to this Agreement; 
 (iv) The filing of a bankruptcy petition by or against a party or the appointment of a receiver for the assets or business of a party that is not
dismissed within sixty (60) days from the date of such filing or appointment; 
 (v) The continuation of any act of force majeure for a
period of six (6) months or longer; or 
 (vi) Election of either party upon two (2) years prior written notice to the other party,
given not earlier than the third anniversary of the FDA Approval of Finished Products. 
  

 -14- 

 14.2 Termination by PLANTEX. This Agreement may be terminated by PLANTEX on the giving of
thirty-six (36) months prior written notice in the event that either: (i) a phase 3 Clinical Trial of a Finished Product has not been initiated on or before December 31, 2006 (or thereafter discontinued prior to successful
completion), or (ii) FDA approval of Finished Product shall not have been obtained by NOVACEA on or before December 31, 2011, provided, however, that after December 31, 2011, and until such time that FDA shall approve the Finished
Product, PLANTEX may not terminate this Agreement so long as NOVACEA or its licensee commits to a minimum purchase quantity of API of [*] grams or such amount necessary to cover the costs of manufacture of such API plus [*] percent, whichever is
greater. 
 14.3 Effect of Termination. Upon termination of this Agreement, all rights and obligations shall cease to exist except for
(i) the payment of unpaid invoices due, (ii) the recovery by a party hereto of damages caused by a breach of this Agreement by the other party, and (iii) the rights and obligations of the Parties which by their express terms survive
termination. 
  

	15.	FORCE MAJEURE  

 Except for the obligation of any
party to make payments to the other party pursuant to this Agreement (which shall not be deferred or extended for any reason), neither party to this Agreement shall be responsible to the other party for any failure to perform or delay in performing
if such failure or delay is due to any strike, riot, civil commotion, sabotage, embargo, war or act of God or other cause beyond its reasonable control. Neither party shall be responsible for any failure to perform or delay in performing due to
inability to obtain deliveries where such inability is caused by the supplier of such party; however, it shall not be an act of force majeure where PLANTEX, at the time it received the forecasts and purchase orders from NOVACEA, failed to make its
best efforts to ascertain the ability of its suppliers to make timely shipments to it, and to inform NOVACEA thereof, as required in this Agreement. 
  

	16.	CONFIDENTIALITY 

 16.1 Confidential
Information. In carrying out the terms of this Agreement it may be necessary that one party disclose to the other certain information, which is considered by the disclosing party to be proprietary and of a confidential nature. As used herein
“Confidential Information” shall mean any and all information, know-how and data, technical or non-technical concerning any finished drug product or bulk active pharmaceutical ingredient, its manufacture, marketing and sale, which
is disclosed under this Agreement as set forth below and which NOVACEA or PLANTEX, as the case may be, considers to be and treats as proprietary and confidential. Confidential Information shall include, but shall not be limited to plans, processes,
compositions, formulations, specifications, samples, systems, techniques, analyses, production and quality control data, testing data, marketing and financial data, and such other information or data relating to any finished drug product or bulk
active pharmaceutical ingredient or its manufacture, marketing or sale. 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 -15- 

 16.2 Non-Use; Non-Disclosure. The receiving party shall not use the Confidential Information for
any purpose other than for purposes of performing its obligations under this Agreement and shall divulge the information only to those of its employees and consultants who have a need to know it as a part of the receiving party’s obligations
hereunder and said employees and consultants shall hold the information in confidence pursuant to this Agreement. The receiving party shall not disclose Confidential Information to any third party without the written consent of the disclosing party.

 16.3 Termination; Exceptions. The obligations of confidentiality as provided herein shall terminate ten (10) years from the
expiration or termination of this Agreement and shall impose no obligation upon the receiving party with respect to any portion of the received information which (i) was known to or in the possession of the receiving party prior to the
disclosure, and not through a prior disclosure by the disclosing party, as documented by business records; or (ii) is or becomes publicly known through no fault attributable to the receiving party; or (iii) is provided to the receiving
party from a source independent of the disclosing party which is not subject to a confidential or fiduciary relationship with the disclosing party concerning the information; or (iv) is developed by the receiving party independently of any
disclosure from the disclosing party and such independent development can be properly demonstrated by the receiving party; or (v) is required to be disclosed by law or court order, provided that notice is promptly delivered to the other party
in order to provide an opportunity to seek a protective order or other similar order with respect to the disclosure of such information and thereafter discloses only the minimum information required to be disclosed in order to comply with the
request, whether or not a protective order or other similar order is obtained by the other party. 
 16.4 Duties Upon Expiration or
Termination. Upon expiration or earlier termination of this Agreement, the receiving party shall, as the disclosing party may direct in writing, either destroy or return to the disclosing party all Confidential Information disclosed together
with all copies thereof, provided, however, the receiving party may retain one archival copy thereof for the purpose of determining any continuing obligations of confidentiality. 
 16.5 Survival. The terms of this Section 16 shall survive termination of this Agreement. 
  

	17.	GENERAL PROVISIONS  

 17.1 Successors and Assigns. (a) The terms and provisions hereof shall inure to the benefit of, and be binding upon, PLANTEX, NOVACEA and their respective successors and permitted assigns. Except as set
forth in subsection (b), below, neither Party may assign any of its rights or obligations under this Agreement without the prior written consent of the other. Any attempt to assign this Agreement in violation of the provisions set forth herein shall
be deemed a default by the assigning Party and null and void. It is hereby acknowledged that the manufacturer of the API is intended to be a third party beneficiary hereunder such that all representations and covenants of NOVACEA contained in this
Agreement shall also inure to the benefit of such manufacturer of API. Furthermore, NOVACEA may assign this Agreement to a Commercialization Partner with whom it enters into an agreement no later than December 31st, 2007 to commercialize the Finished Product. 
  

 -16- 

 (b) Either Party may assign this Agreement to an Affiliate of such Party upon prior written notice
thereof to the non-assigning Party. Such notice shall be accompanied by an undertaking, in form reasonably satisfactory to the non-assigning Party, assuring that the assigning Party shall not be released of any obligations and remain primarily
liable for the obligations of the assigning Party hereunder. Either Party may also assign this Agreement to a non-Affiliate upon prior written notice to the non-assigning Party in the event of a merger or acquisition of the assigning Party or the
sale by the assigning Party to such non-Affiliate of all or substantially all of the assets (including, without limitation, the NDA or ANDA for the Finished Products) to which this Agreement relates provided that such successor has assumed all
liabilities of the assigning Party hereunder. 
 17.2 Notices. Any notice, request, instruction or other communication required or
permitted to be given under this Agreement shall be in writing and shall be given by sending such notice properly addressed to the other party’s address shown below (or any other address as either party may indicate by notice in writing to the
other from time to time) (i) by hand or by prepaid registered or certified mail, return receipt requested, in either of such cases which notice shall be deemed delivered upon receipt, (ii) via telecopy, facsimile or telegram, in any of
such cases which notice shall be deemed delivered upon receipt, or (iii) via nationally recognized overnight courier, in which case such notice shall be deemed delivered upon receipt. All such notices shall be deemed given when received.

  

			
	If to PLANTEX:	    	PLANTEX USA Inc.
		    	2 University Plaza
		    	Suite 305
		    	Hackensack, New Jersey 07601
		    	Attention: President
		    	Fax Number: 1-201-343-3833
		
	If to NOVACEA:	    	NOVACEA, Inc.
		    	601 Gateway Blvd.
		    	Suite 800
		    	South San Francisco, CA 94080
		    	Attention: President
		    	Fax Number: 1-650-228-1088

 17.3 Publicity. Except to the extent required by law or deemed appropriate by legal counsel
to comply with securities laws, including the furnishing of a press release and the filing of such documents and information with the Securities and Exchange Commission as may be required by federal securities laws and the filing of any report,
statement or document required by any other federal or state regulatory body, neither party to this Agreement shall publish, disclose or otherwise announce the existence of this Agreement or the terms hereof with out the consent of the other party,
which consent shall not be unreasonably withheld. 
 17.4 Waiver. The failure of either party to terminate or seek redress for a
breach of, or to insist upon strict performance of any term, covenant, condition or provision contained in, this Agreement shall not prevent a similar subsequent act from constituting a breach of this Agreement. 
  

 -17- 

 17.5 Governing Law. This Agreement shall be governed and construed in accordance with the laws of
the State of New Jersey, without regard to principles of conflicts of law. 
 17.6 Counterparts. This Agreement may be executed in any
number of counterparts, each of which shall be an original as against either Party whose signature appears thereon, but all of which taken together shall constitute but one and the same instrument. 
 17.7 Independence of Parties. NOVACEA and PLANTEX shall at all times act as independent parties without the right or authority to bind the other
with respect to any agreement, representation or warranty made with or to any third party. Except as otherwise stated herein, NOVACEA and PLANTEX each shall be responsible for all costs, expenses, taxes and liabilities arising from the conduct of
its own business, as well as from the activities of its officers, directors, agents or employees, and each shall hold harmless and indemnify the other from any such obligations. 
 17.8 Entire Agreement. This Agreement contains the entire and only agreement between the parties with respect to the manufacture and sale of the
API and no oral statements or representations or written matter not contained in this Agreement shall have ally force or effect. This Agreement shall not be amended or modified in any way except by writing executed by authorized representatives of
both parties. 
 17.9 Partial Invalidity. If any portion of this Agreement is determined to be illegal or otherwise unenforceable by
agreement of the parties by an arbitrator, by a court of competent jurisdiction or by an administrative agency of competent jurisdiction, such section, to the extent permitted by law, shall be treated as deleted from this Agreement and the remaining
portions of this Agreement shall continue to be in full force and effect according to the terms hereof. 
 17.10 Headings. The
headings and captions used in this Agreement are for the convenience of reference only and shall not be construed as part of this Agreement or as a limitation on the scope of any provisions of this Agreement. 
 IN WITNESS WHEREOF, the parties hereto have set their hands and seals on the date written at the beginning hereof. 
  

									
	PLANTEX USA, INC.	 		 	NOVACEA, INC.
					
	By:	 	 /s/ George Svokos
	 		 	By:	 	 /s/ John Walker

	Name:	 	George Svokos	 		 	Name:	 	John Walker
	Title:	 	President	 		 	Title:	 	Chief Executive Officer
					
	By:	 	 /s/ Allen Lefkowitz
	 		 		 	
	Name:	 	Allen Lefkowitz	 		 		 	
	Title:	 	CFO	 		 		 	

  

 -18- 

 Appendix A 

 

 
 PRODUCT 
 SPECIFICATIONS 
 AND 
 CERTIFICATE OF ANALYSIS 
 Page 1 
  

							
	Product Name:	  	Calcitriol	  	Order No.:	  	
				
	Control No.:	  	[*]	  	Customer Name/No.:	  	Drug Master File
				
	Lab Record No.:	  	-	  	Quantity:	  	
				
	Manufacturing Site:	  	[*]	  	Analysis Date:	  	
				
	Manufacturing Date:	  		  	Re-test Date:	  	**************
				
	Packaging and Storage:	  	Store under [*], in [*], [*], Temp. [*]	  		  	

					
			
	TESTS AND METHODS	  	SPECIFICATIONS	  	RESULTS*
	
	IN-HOUSE TESTS
			
	Description	  	[*]	  	
			
	 Identification
 A: [*]
 B:[*]
	  	[*]	  	
			
	[*]	  	[*]	  	%
			
	Related compounds [*]	  	 Not more than [*]%
 Not more than [*]%
 Not more than [*]%
 Not more than [*]%
 Not more than [*]%
	  	 %
 %
 %
 %
 %
 %

			
	Assay [*]	  	Between [*]% to [*]%	  	%
			
	 Residual solvents
 [*]
	  	
 Not more than [*]ppm
 Not more
than [*]ppm
 Not more than [*]ppm
 Not more than
[*]ppm
 Not more than [*]ppm
	  	 ppm
 ppm

 ppm
 ppm
 ppm

  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

	
	

	
	Ramat-Hovav P.O. Box 2049 Emek-Sara Be’er-Sheva 84874 Tel. 07-6509555, Fax. 07-6509500

 

 
 PRODUCT 
 SPECIFICATIONS 
 AND 
 CERTIFICATE OF ANALYSIS 
 Page 2 
  

							
	Product Name:	  	Calcitriol	  	Order No.:	  	
				
	Control No.:	  	[*]	  	Customer Name/No.:	  	Drug Master File
				
	Lab Record No.:	  	-	  	Quantity:	  	
				
	Manufacturing Site:	  	[*]	  	Analysis Date:	  	
				
	Manufacturing Date:	  		  	Re-test Date:	  	**************
				
	Packaging and Storage:	  	Store under [*], in [*], [*], Temp. [*]	  		  	

					
			
	TESTS AND METHODS	  	SPECIFICATIONS	  	RESULTS*

 Remarks: 
 ... Conforms to the requirements of the IN-HOUSE Specifications. 
  

					
	Released by Quality Control Manager:	  	Date:	  	Signature:
	 Dr. AMIRA ROTTMAN
	  	 11 June 2001
	  	

  

	(*)	Upon completion of the ‘Results’ column this document becomes a certificate of analysis.
                                End of C.O.A. 

  

	
	

	
	Ramat-Hovav P.O. Box 2049 Emek-Sara Be’er-Sheva 84874 Tel. 07-6509555, Fax. 07-6509500Amended and Restated Exclusive License Agreement

 Exhibit 10.2 
 AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT 
 BETWEEN OHSU AND 
 NOVACEA, INC. 
 This Amended and Restated
Agreement (hereinafter this “Agreement”) is made and entered into as of May 25, 2007 (“Effective Date”) between the Oregon Health & Science University (hereinafter OHSU) having offices at
2525 S.W. First Avenue, Suite 120, Portland, Oregon 97201, and Novacea, Inc. (formerly known as D-Novo Therapeutics, Inc.) (hereinafter Licensee), a Delaware corporation having offices at 601 Gateway Blvd., Suite 800, South San Francisco,
California 94080; and hereby amends and restates the Exclusive License Agreement between OHSU and Licensee effective June 27, 2001 (the “Original License Agreement”). 
  

	1.	BACKGROUND 

  

	1.01	In the course of fundamental research programs at OHSU, inventions were conceived which relate to Vitamin D and its analogs in oncology and other disease therapies. The
intellectual property rights resulting from these inventions (and licensed through this Agreement) are subject to the conditions set forth in 37 CFR Part 401. 

  

	1.02	By assignment of the inventions as described in OHSU Disclosure Number 97/413 from the inventors, OHSU is the owner of certain patent rights and desires to grant
licenses under those rights to Licensee for development of products and processes for public use and benefit. These patent rights include, but are not limited to, those rights in PCT Patent Application #WO 99/49870 “Vitamin D and its
Analogs in the Treatment of Tumors and Other Hyperproliferative Disorders” and other patent applications related to the pulsatile high-dose administration of Vitamin D and analogs in tumors and other hyperproliferative disorders, including, but
not limited to those listed in Appendix A to this Agreement. 

  

	1.03	Licensee desires to develop processes and methods and marketable products for public use and benefit by using Licensed Patent Rights. 

  

	1.04	OHSU and Licensee entered into an agreement dated June 27th, 2001, the Original License Agreement, which was subsequently amended on November 21, 2005.

  

	1.05	OHSU and Licensee hereby seek to further amend and restate the Original License Agreement as indicated herein. 

  

	2.	DEFINITIONS 

  

	2.01	“Affiliate” means any legal entity directly or indirectly controlling, controlled by or under common control with Licensee. Any Affiliate or any joint
venture or other entity formed by Licensee that distributes Licensed Products or Licensed Processes shall execute (a) this Agreement or (b) a written joinder agreement in a form satisfactory to OHSU, and
will be a Licensee for the purposes of this Agreement (other than for the purposes of Section 6.01). Licensee shall be responsible for such Affiliate’s or entity’s performance of its obligations under this
Agreement. 

	2.02	“Development Plan” means a plan(s) for the development and/or marketing of the Licensed Patent Rights that demonstrates Licensee’s capability to
bring the Licensed Patent Rights to practical application as such term is defined in 35 U.S.C. §201(f). 

  

	2.03	“First Commercial Sale” means the initial transfer by or on behalf of Licensee or its sublicensees of Licensed Products or the initial practice of a
Licensed Process by or on behalf of Licensee or its sublicensees in exchange for cash or some equivalent to which value can be assigned for the purpose of determining Net Sales. For the avoidance of doubt, (1) sales for
test marketing, sampling and promotional uses, clinical trial purposes or compassionate or similar use and (2) transfers of Licensed Products, whether by sale or otherwise, or practice of the Licensed Process, as between
Affiliates of Licensee, or Affiliates of its sublicensees, will not constitute a First Commercial Sale or a sale for the purpose of determining Net Sales, provided that (i) the Affiliate to whom the
transfer is made is not an end-user for the purpose of patient administration, and (ii) if Licensee, or a sublicense, sells a Licensed Product or Licensed Process to an Affiliate for resale, Net Sales will
include any amounts received by such Affiliate from third parties on the resale of such Licensed Product or Licensed Process. 

  

	2.04	“Government” means the government of the United States of America. 

  

	2.05	“Licensed Fields of Use” means all prophylactic, therapeutic, and diagnostic uses in humans and/or animals. 

  

	2.06	“Licensed Know-How” means all proprietary information, methods, processes, techniques, data and biologic materials (including, without limitation, pre-clinical and
clinical data) which are in the possession of or controlled by OHSU during the term of this Agreement, which OHSU is free to license or sublicense, and which is necessary or useful for the manufacture, use or sale of a
Licensed Product in the Licensed Fields of Use or to practice any Licensed Process in the Licensed Fields of Use in the Licensed Territory. Except as otherwise expressly agreed by the parties, the license to
Licensee of Licensed Know-How set forth above shall not obligate OHSU to conduct additional research or otherwise initiate any action with respect to creation of new Licensed Know-How. 

  

	2.07	“Licensed Patent Rights” shall mean: 

  

	 	a)	U.S. and foreign patent applications and patents listed in Appendix A or subsequently added to Appendix A by agreement of the parties, all divisions and continuations of these
applications, all patents issuing from such applications, divisions, and continuations, and any reissues, reexaminations, and extensions of all such patents; 

  

	 	b)	and to the extent that the following contain one or more claims directed to the invention or inventions claimed in a) above: i) continuations-in-part of a) above; ii) all divisions
and continuations of these continuations-in-part; iii) all patents issuing from such continuations-in-part, divisions, and continuations; and iv) any reissues, reexaminations, and extensions of all such patents.  

  

 - 2 - 

 Licensed Patent Rights shall not include claims in b) above to the extent that they are directed
to new matter which is not the disclosed in the specifications of a) above. 
  

	2.08	“Licensed Product(s)” means tangible materials which, in the course of manufacture, use, or sale would be covered by one or more claims of the Licensed Patent
Rights that have not been held invalid or unenforceable by an unappealed or unappealable judgment of a court of competent jurisdiction. 

  

	2.09	“Licensed Process(es)” means processes which, in the course of being practiced would be covered by one or more claims of the Licensed Patent Rights that have
not been held invalid or unenforceable by an unappealed or unappealable judgment of a court of competent jurisdiction. 

  

	2.10	“Licensed Territory” means the world. 

  

	2.11	“Net Sales” means the aggregate gross amount invoiced by Licensee or its Affiliates on all sales or transfers for consideration of Licensed
Product or Licensed Process in the Licensed Territory to a third party, less the following deductions to the extent such deductions are documented and (i) listed in the invoice as a credit or charge added to the unit price
of a Licensed Product or Licensed Process or (ii) directly paid or actually incurred and not reimbursed to or recovered by Licensee or its Affiliates with respect to the sale of such Licensed Product or
Licensed Process: 

  

	 	a)	bad debts actually written off which are attributable to sales of Licensed Product or Licensed Process; 

  

	 	b)	trade, quantity and cash discounts and any other adjustments, including, without limitation, those granted on account of price adjustments, billing errors, rejected goods, damaged
goods, returns, recalls, rebates, chargeback rebates, fees, reimbursements or similar payments granted or given to wholesalers or other distributors, buying groups, health care insurance carriers or other institutions: 

  

	 	c)	freight, packing, handling, shipping, postage and insurance charges to the extent that they are included in the price or otherwise paid by the purchaser; 

 

	 	d)	customs or excise taxes, including, without limitation, import duties, sales tax and other taxes (except income taxes) or duties relating to sales, 

  

	 	e)	distribution, packing, handling and transportation charges for Licensed Product to the extent that they are included in the price or otherwise paid by the customer;

 The foregoing adjustments shall be consistent with customary accounting practices within the selling party and its
Affiliates (or their respective sublicensees) and in accordance with United States Generally Accepted Accounting Principles (“GAAP”), consistently applied. 
  

 - 3 - 

 It is understood, however, that in certain countries, Licensee or its Affiliates may
commercialize Licensed Products through a third party distributor or agent under an arrangement in which Licensee or its Affiliates, (x) transfer the Licensed Product to such distributor or agent at a fixed price
that is not necessarily related to the final selling price of the distributor or agent, and (y) are not responsible for marketing and promoting such Licensed Product in such countries and receive no compensation from the sale of such
Licensed Products by the distributor or agent. To the extent that such third party distributors or agents would be considered “sublicensees”, the OHSU and Licensee agree that the gross invoiced sales prices for the
sale of the Licensed Product by Licensee or its Affiliates to such third parties shall be the price to be used for purposes of computing Net Sales in such countries provided, however, that (i) such gross invoiced
sales prices are determined prior to any deductions by the selling party, (ii) the selling party receives no form of consideration other than such gross invoiced sales prices from such third party distributors or agents. 
  

	2.12	“Reasonable Commercial Efforts” means efforts and resources commonly used in the pharmaceutical industry for a drug of similar commercial potential at a similar
stage in its lifecycle, taking into consideration its safety and efficacy, the cost to develop and commercialize the product, its competitiveness compared to alternative products, the proprietary position of the product, the scope, timing and
likelihood of regulatory approvals, the profitability of the product and other relevant factors. 

  

	2.13	“Trigger Event” means any of the following: 

  

	 	a)	if Licensee becomes insolvent, bankrupt or generally fails to pay its debts as such debts become due; is adjudicated insolvent or bankrupt; admits in writing its inability to
pay its debts; or shall suffer a custodian, receiver or trustee for it or substantially all of its property to be appointed and, if appointed without its consent, not be discharged within thirty (30) days; makes an assignment for the benefit of
creditors; or suffers proceedings under any law related to bankruptcy, insolvency, liquidation or the reorganization, readjustment or the release of debtors to be instituted against it and, if contested by it, not dismissed or stayed within ten
(10) days; 

  

	 	b)	if proceedings under any law related to bankruptcy, insolvency, liquidation, or the reorganization, readjustment or the release of debtors are instituted or commenced by
Licensee; 

  

	 	c)	if any order for relief is entered relating to any of the proceedings described in Paragraphs 2.13(a) or (b); 

  

	 	d)	if Licensee shall call a meeting of its creditors with a view to arranging a composition or adjustment of its debts; 

  

 - 4 - 

	 	e)	if Licensee shall by any act or failure to act indicate its consent to, approval of or acquiescence in any of the proceedings described in Paragraphs 2.13 (a), (b),
(c) or (d); or 

  

	 	f)	if Licensee fails to make commercially reasonable efforts to cure any material breach by a sublicensee of any provision of its agreement with Licensee that is directly
related to the Licensed Patent Rights and would have a material adverse impact on OHSU’s rights under this Agreement, or if after Licensee makes such commercially reasonable efforts and sublicensee is still in
material breach for which there is no other adequate remedy other than termination, Licensee fails to terminate such sublicense agreement within a reasonable period of time, but in no event longer than one hundred eighty (180) days.

  

	3.	GRANT OF RIGHTS 

  

	3.01	OHSU hereby grants and Licensee accepts, subject to the terms and conditions of this Agreement, an exclusive license to Licensee under the Licensed
Patent Rights and Licensed Know-How in the Licensed Territory to make, have made, use, offer for sale, sell, export, and import any Licensed Products in the Licensed Fields of Use and to practice and have practiced
any Licensed Processes in the Licensed Fields of Use. 

  

	3.02	At no cost to Licensee, for two (2) years from the effective date of the Original License Agreement: 1) for all inventions conceived within that two
(2) years that are improvements to the patents and patent applications listed in Appendix A, Licensee shall have the right to add said patents and patent applications to Appendix A; and, 2) Licensee shall have the right to add
patents and patent applications acquired or licensed by or to OHSU that relate to the pulsatile high-dose administration of Vitamin D and analogs in tumors and other hyperproliferative disorders. In that event, the terms and conditions
governing said additional patent applications and patents added to Appendix A shall be the terms and conditions provided for herein, as modified by any further written agreement of the parties. After two (2) years from the effective date of the
Original License Agreement, the parties agree that Licensee will have the first right to negotiate in good faith regarding any additional patent rights that relate to pulsatile high-dose administration of Vitamin D and analogs in
tumors and other hyperproliferative disorders that Licensee desires to acquire from OHSU. 

  

	3.03	This Agreement confers no license or rights by implication, estoppel, or otherwise under any patent applications or patents of OHSU other than Licensed Patent
Rights regardless of whether such patents are dominant or subordinate to Licensed Patent Rights. 

  

	3.04	The license of Paragraph 3.01 above is exclusive, except that (i) OHSU may practice and use the Licensed Patent Rights and Licensed Know-How for
educational and non-commercial research purposes, (ii) OHSU may grant non-exclusive licenses to other universities, academic institutions, and nonprofit research organizations, with whom it has a contractual non-commercial research
collaboration, to practice the Licensed Patent Rights and Licensed Know-How for educational and non-commercial research purposes, and (iii) the U.S. government may use the Licensed Patent Rights as provided for in Paragraph
5.01. 

  

 - 5 - 

	4.	SUBLICENSING 

  

	4.01	Upon written approval by OHSU, which approval will not be unreasonably withheld, Licensee may enter into sublicensing agreements under the Licensed Patent
Rights. 

  

	4.02	Licensee agrees that any sublicenses granted by it shall provide that the obligations to OHSU of Paragraphs 5.01, 5.02, 8.01, 10.01, 10.02, 12.01-12.05, and
13.01-13.10 of this Agreement shall be binding upon any sublicensee as if it were a party to this Agreement. Licensee further agrees to attach copies of these Paragraphs to all sublicense agreements. 

  

	4.03	Licensee shall have the right to enter into sub-licensing arrangements for the rights, privileges and licenses granted hereunder. Any sublicensee shall have the right to
grant further sublicenses as necessary to meet its obligations under any sublicense agreement with Licensee, provided that there be no dilution of the royalties due to OHSU under Paragraph 6.02, 6.03, and 6.04. Any further sublicensee
will have no right to grant further sublicenses. 

  

	4.04	Any sublicenses granted by Licensee shall provide for the termination of the sublicense, or the conversion to a license directly between such sublicensees and OHSU, at
the option of the sublicensee, upon termination of this Agreement under Article 13, provided that, at the time of the election of such conversion, such sublicensee is not in material breach of its sublicense agreement with Licensee.
Such conversion is contingent upon acceptance by the sublicensee of the provisions of this Agreement. 

  

	4.05	Licensee agrees to forward to OHSU a copy of each fully executed sublicense agreement postmarked within thirty (30) days of the execution of such agreement,
provided that Licensee may, in its sole discretion, redact from such copy technical information that does not relate to Licensed Patent Rights, and economic or competitive terms that do not relate to consideration paid for, or other
financial obligations relating to, the grant of the sublicense under the Licensed Patent Rights. 

  

	4.06	In the event of a default under Article 13 hereunder, all portions relating to this Agreement of any payments then or thereafter due to Licensee from each of its
sublicensees shall, to the extent not yet paid to Licensee as of the effective date of any termination by OHSU due to such uncured default, upon notice from OHSU to any such sublicensee, become owed directly to OHSU for
the account of Licensee; provided that OHSU shall remit to Licensee the amount by which such payments in the aggregate exceed the total owed by Licensee to OHSU. 

  

	4.07	Even if Licensee enters into sublicenses, Licensee remains primarily liable to OHSU for all of Licensee’s duties and obligations contained in this
Agreement. 

  

 - 6 - 

	5.	STATUTORY AND OHSU REQUIREMENTS AND RESERVED GOVERNMENT RIGHTS 

  

	5.01	If and only to the extent required and applicable under 35. U.S.C. §202(c)(4), OHSU reserves on behalf of the Government an irrevocable, nonexclusive,
nontransferable, royalty-free license for the practice of all subject inventions, as such term is defined in 35 U.S.C §201(e), licensed under the Licensed Patent Rights. 

  

	5.02	If and only to the extent required and applicable under 35 U.S.C §204, Licensee agrees that products used or sold in the United States embodying Licensed Patent
Rights that are subject inventions as defined in 35 U.S.C. §201(e) shall be manufactured substantially in the United States, unless a written waiver is obtained in advance from the Government. 

  

	6.	ROYALTIES AND REIMBURSEMENT 

  

	6.01	

  

	 	a)	Promptly following the execution of the Original License Agreement, Licensee shall issue to OHSU as a license issuance royalty 800,000 shares of the Common
Stock of Licensee, which shares will represent approximately [*]% of the shares of the Common Stock of Licensee deemed to be outstanding on a fully-diluted basis after giving effect to such issuance. A copy of a Term Sheet relating to
Licensee’s proposed Series A-1 Preferred Stock and Series A-2 Preferred Stock financing transactions wherein Licensee will raise an aggregate of $[*] is attached hereto as Appendix B. It is anticipated that after the closing of
the Series A-1 Preferred Stock financing, wherein it is anticipated that Licensee will raise $[*], the shares issued to OHSU will represent approximately [*]% of the Common Stock of Licensee deemed to be outstanding on a fully
diluted basis and after the closing of the Series A-2 Preferred Stock financing transaction, wherein it is anticipated that Licensee will raise an aggregate of $[*], the shares issued to OHSU will represent approximately [*]% of the
Common Stock of Licensee deemed to be outstanding on a fully-diluted basis. The shares of Common Stock to be issued to Licensee shall not be subject to forfeiture and shall not be used as an offset or credit against future royalties.
This Agreement is conditioned upon Licensee raising cash equity on substantially the terms described in the Series A-1/Series A-2 Term Sheet attached as Appendix B. 

  

	 	b)	Concurrently with the issuance of the shares of Common Stock to OHSU, OHSU shall execute an investment representation letter substantially in the form attached hereto
as Appendix C, and OHSU and Licensee shall execute a Stock Restriction Agreement substantially in the form attached hereto as Appendix D (the “Stock Restriction Agreement”). Licensee warrants and
represents that (i) the Stock Restriction Agreement is no more restrictive to the stockholder than any other restriction agreement now in use or contemplated to be entered into between 

  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 - 7 - 

	 	 
Licensee and holders of its Common Stock and (ii) all holders of Common Stock of Licensee who are employees and/or officers of
Licensee have entered into or will enter into a restriction agreement which includes restrictions substantially the same as those set forth in the Stock Restriction Agreement. 

  

	 	c)	Licensee shall grant to OHSU the same “piggyback” registration rights as are granted to investors (the “Investors”) participating in
Licensee’s Series A-1 Preferred Stock and Series A-2 Preferred Stock financing transactions. Licensee will furnish to OHSU quarterly and annual financial statements and such other financial information and reports as are
furnished to the Investors, with such statements, information and reports being furnished to OHSU at the same time they are furnished to the Investors. 

  

	6.02	Licensee agrees to pay OHSU earned royalties as follows: 

  

	 	a)	[*] percent ([*]%) royalty on Net Sales by Licensee. 

  

	 	b)	In the event that any Licensed Product or practice of Licensed Process incorporates other patent rights or rights in other intellectual property for which royalties
are due by Licensee, then Licensee shall not be required to stack its royalty payments, and the parties shall negotiate in good faith among Licensee, OHSU and the other holders of the intellectual property rights to
determine the division of the royalties so that Licensee shall not be required to pay an aggregate royalty of more than [*] percent ([*]%) of Net Sales. However, in no event shall the share of OHSU’s royalty be less than
[*] percent ([*]%) of Net Sales of the Licensed Products or Licensed Processes. 

  

	6.03	Licensee agrees to pay OHSU milestone royalties and market launch royalties as follows: 

  

	 	a)	$[*] upon successful completion of [*] for any product covered by Licensed Patent Rights. 

  

	 	b)	$[*] upon successful completion of [*] for any product, covered by Licensed Patent Rights. 

  

	 	c)	$[*] upon successful completion of [*] for any product covered by Licensed Patent Rights. 

  

	 	d)	In the event that any product covered by Licensed Patent Rights fails after completion of Phase III clinical trials, and a substitute product (backup compound) covered by the
Licensed Patent Rights must be substituted for the same indication, no additional Phase I or II milestone royalties shall be due for any backup compound(s). 

  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 - 8 - 

	 	e)	$[*] upon [*] for any product covered by Licensed Patent Rights. 

  

	 	f)	Milestone royalties set forth in Paragraphs 6.03(a)-(c) are nonrefundable, and shall have no credit or offset against future royalties. Market launch royalties set forth in
Paragraph 6.03(e) are refundable and are to be fully credited against future royalties due. 

  

	6.04	Licensee shall pay to OHSU a sublicensing royalty of fifteen percent (15%) of any monies or other consideration received by Licensee from any sublicensing
of the Licensed Patent Rights, including without limitation any sublicense initiation fees, milestone payments, royalties on sales, and any premium on any equity investment by sublicensees. Any non-cash consideration received by the
Licensee from such sublicensees shall be valued at its fair market value as of the date of receipt. However, said payments from any sublicensee shall not include consideration received for cost reimbursement of R&D services, and no amount
shall be due to OHSU from Licensee for consideration received as reimbursement for such R&D services. 

  

	6.05	A claim of a patent or patent application licensed under this Agreement shall cease to fall within the Licensed Patent Rights for the purpose of computing the earned
royalty payments in any given country on the earliest of the dates that a) the claim has been abandoned but not continued, b) the patent expires, c) the patent is no longer maintained by OHSU, or d) all claims of the Licensed Patent
Rights have been held to be invalid or unenforceable by an unappealed or unappealable decision of a court of competent jurisdiction or administrative agency. 

  

	6.06	No multiple royalties shall be payable to OHSU because any Licensed Products or Licensed Processes are covered by more than one of the Licensed Patent
Rights. 

  

	6.07	On sales of Licensed Products and Licensed Processes by Licensee made in other than an arm’s-length transaction. The value of the Net Sales
attributed under this Article 6 to such a transaction shall be that which would have been received in an arm’s-length transaction, based on sales of like quantity and quality products on or about the time of such transaction.

  

	6.08	As an additional royalty, Licensee agrees to pay OHSU, within sixty (60) days of OHSU’s submission of a statement and request for payment, an amount
equivalent to all reasonable expenses previously incurred by OHSU in the preparation, filing, prosecution, and maintenance of Licensed Patent Rights. Licensee further agrees to pay OHSU quarterly, within sixty
(60) days of OHSU’s submission of a statement and request for payment, a royalty amount equivalent to all such patent expenses incurred during, the previous calendar quarter, as of the date the statement and request for payment is
sent by OHSU to Licensee. Licensee may elect to surrender its rights in any country of the Licensed Territory under any Licensed Patent Rights upon sixty (60) days’ written notice to OHSU and owe
no payment obligation under this Paragraph 6.08 for subsequent patent-related expenses incurred in that country. 

  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 - 9 - 

	6.09	Royalties due under this Article 6 shall be paid in U.S. dollars. For conversion of foreign currency to U.S. dollars, the conversion rate shall be the rate quoted in The Wall Street
Journal on the last business day of the applicable calendar quarter or half-year, as applicable, that the payment is due. All checks and bank drafts shall be drawn on United States banks and shall be payable to Oregon Health & Science
University at the address shown on the Signature Page below. Any loss of exchange, value, taxes, or other expenses incurred in the transfer or conversion to U.S. dollars shall be paid entirely by Licensee. 

  

	6.10	Amounts that are not paid when due shall accrue interest from the due date until paid, at a rate equal to one percent (1.0%) per month or part thereof (or the maximum allowed
by law, if less). 

  

	7.	DOMESTIC AND FOREIGN PATENT FILING, PROSECUTION, AND MAINTENANCE 

  

	7.01	OHSU in consultation with Licensee, and with Licensee’s approval, shall be responsible for the preparation, filing, prosecution, and maintenance of any and
all patent applications or patents included in the Licensed Patent Rights. OHSU shall use patent counsel selected by Licensee for said preparation, filing, prosecution, and maintenance, OHSU shall promptly furnish copies
of all patent-related documents to Licensee. 

  

	7.02	Each party shall promptly inform the other as to all matters that come to its attention that may affect the preparation, filing, prosecution, or maintenance of the Licensed
Patent Rights and permit each other to provide comments and suggestions with respect to the preparation, filing, and prosecution of Licensed Patent Rights, which comments and suggestions shall be considered by the other party.

  

	8.	RECORD KEEPING 

  

	8.01	Licensee agrees to keep accurate and correct records of Licensed Products made, used, or sold and Licensed Processes practiced under this Agreement
appropriate to determine the amount of royalties due OHSU. Licensee shall require its sublicensees to keep similar records so as to enable Licensee to audit any such sublicensees in order to meet its record keeping obligations
under this Agreement. Licensee’s records shall be retained for at least three (3) years following a given reporting period. Licensee’s records shall be available during normal business hours for inspection at the
expense of OHSU by an accountant or other designated auditor selected by OHSU for the sole purpose of verifying reports and payments hereunder. The accountant or auditor shall only disclose to OHSU information relating to the
accuracy of reports and payments made under this Agreement. If an inspection shows an under reporting or underpayment in excess of five percent (5%) for any twelve (12) month period, then Licensee shall reimburse OHSU
for the cost of the inspection at the time Licensee pays the unreported royalties, including any interest charges as required by Paragraph 6.10 of this Agreement. All payments required under this Paragraph 8.01 shall be due within
thirty (30) days of the date OHSU provides Licensee notice of the payment due. 

  

 - 10 - 

	9.	REPORTS ON PROGRESS, BENCHMARKS, SALES, AND PAYMENTS 

  

	9.01	Within ninety (90) days of the Effective Date of this Agreement, Licensee shall provide OHSU with a written, executive summary of any current
Development Plan being used by Licensee, or, if applicable, with any exclusive sublicensee. 

  

	9.02	Licensee shall provide written annual reports on its product development progress or efforts to commercialize for each of the Licensed Fields of Use within sixty
(60) days after December 31 of each calendar year. These progress reports shall include, but not be limited to, progress on research and development, status of applications for regulatory approvals, manufacturing, sublicensing, marketing,
and sales during the preceding calendar year, strategic alliances with industry counterparts, as well as plans for the present calendar year. Licensee agrees to provide any additional data reasonably required by OHSU to evaluate
Licensee’s performance. 

  

	9.03	Licensee shall report to OHSU the date of the First Commercial Sale of each Licensed Product or Licensed Process in each country in the
Licensed Territory within thirty (30) days of such occurrence. 

  

	9.04	Licensee shall submit to OHSU within sixty (60) days after each calendar half-year ending June 30 and December 31 a royalty report setting forth for the
preceding half-year period the amount of the Licensed Products sold or Licensed Processes practiced by or on behalf of Licensee or its sublicensees in each country within the Licensed Territory, the Net Sales, the
milestones achieved, and the amount of royalty accordingly due. With each such royalty report; Licensee shall submit payment of the earned royalties due. If no earned royalties are due to OHSU for any reporting period, the written
report shall so state. The royalty report shall be certified as correct by an authorized officer of Licensee and shall include a detailed listing of all deductions made under Paragraph 2.09 to determine Net Sales made under Article 6
to determine royalties due. 

  

	9.05	Licensee agrees to forward semi-annually to OHSU a copy of such reports received by Licensee from its sublicensees during the preceding half-year period as
shall be pertinent to a royalty accounting to OHSU by Licensee for activities under the sublicense. 

  

	9.06	All plans and reports required by this Article 9 and marked “Confidential” by Licensee shall be treated by OHSU as commercial and financial information
obtained from a person, and as privileged and confidential and, to the extent permitted by the Oregon Public Records Law and other applicable laws, shall not be disclosed to any third party. 

  

	10.	PERFORMANCE 

  

	10.01	Licensee shall use Reasonable Commercial Efforts to introduce the Licensed Products into the commercial market or apply the Licensed Processes to
commercial use as soon as practicable. The efforts of a sublicensee shall be considered the efforts of Licensee. 

  

	10.02	If and only to the extent applicable under 35 U.S.C. §200, upon the First Commercial Sale until the expiration of this Agreement, Licensee shall use
Reasonable Commercial Efforts to keep Licensed Products and Licensed Processes reasonably accessible to the public. 

  

 - 11 - 

	11.	INFRINGEMENT AND PATENT ENFORCEMENT 

  

	11.01	OHSU and Licensee agree to notify each other promptly of each infringement or possible infringement, as well as any facts which may affect the validity, scope, or
enforceability of the Licensed Patent Rights of which either party becomes aware. 

  

	11.02	Pursuant to this Agreement and the provisions of Chapter 29 of Title 35, United States Code, Licensee may (a) bring suit in its own name, at its own expense, and
on its own behalf for infringement of presumably valid claims in the Licensed Patent Rights; (b) in any such suit, enjoin infringement and collect for its use, damages, profits, and awards of whatever nature recoverable for such
infringement; and (c) settle any claim or suit for infringement of the Licensed Patent Rights. Licensee shall take no action to compel. OHSU either to initiate or to join in any such suit for patent infringement.
Licensee may request OHSU to initiate or join any such suit if necessary to avoid dismissal of the suit. Should OHSU be made a party to any such suit, Licensee shall reimburse OHSU for any costs, expenses, or fees
which OHSU incurs as a result of such motion or other action, including any and all costs incurred by OHSU in opposing any such motion or other action. Upon Licensee’s payment of all costs incurred by OHSU as a
result of Licensee’s joinder motion or other action, these actions by Licensee will not be considered a default in the performance of any material obligation under this Agreement. In all cases, Licensee, agrees to
keep OHSU reasonably apprised of the status and progress of any litigation. Before Licensee commences an infringement action or interference proceedings, Licensee shall notify OHSU and give careful consideration to the
views of OHSU in deciding whether to bring suit. 

  

	11.03	In any infringement action or interference proceedings commenced under Paragraph 11.02, the expenses including costs, fees, attorney fees, and disbursements, shall be paid by
Licensee. Up to [*] percent ([*]%) of such expenses may be credited against the royalties payable to OHSU under Paragraph 6.02 under the Licensed Patent Rights in the country in which such a suit is filed. In the event that [*]
percent ([*]%) of such expenses exceed the amount of royalties payable by Licensee in any calendar year, the expenses in excess may be carried over as a credit on the same basis into succeeding calendar years. Any recovery made by
Licensee, through court judgment or settlement, first shall be applied to reimburse OHSU for royalties withheld as a credit against litigation expenses and then to reimburse Licensee for its litigation expense. Any remaining
recoveries shall be shared equally by Licensee and OHSU. 

  

	11.04	OHSU shall cooperate fully with Licensee in connection with an infringement action or interference proceedings initiated under Paragraph 11.02. OHSU agrees
promptly to provide access to all necessary documents and to render reasonable assistance in response to a request by Licensee. 

  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 - 12 - 

	11.05	In the event that a declaratory judgment action alleging invalidity or non-infringement of any of the Licensed Patent Rights shall be brought against Licensee or
raised by way of counterclaim or affirmative defense in an infringement suit brought by Licensee under Paragraph 11.02, pursuant to this Agreement and the provisions of Chapter 29 of Title 35, United States Code or other statutes,
Licensee may a) defend the suit in its own name, at its own expense, and on its own behalf for presumably valid claims in the Licensed Patent Rights; b) in any such suit, ultimately to enjoin infringement and to collect for its use,
damages, profits, and awards of whatever nature recoverable for such infringement; and c) settle any claim or suit for declaratory judgment involving the Licensed Patent Rights; provided, however, that OHSU shall have the first right
to take such actions and shall have a continuing right to intervene in such suit. Licensee shall take no action to compel OHSU either to initiate or to join in any such declaratory judgment action. Licensee may request
OHSU to initiate or join any such suit if necessary to avoid dismissal of the suit. Should OHSU be made a party to any such suit by motion or any other action of Licensee, Licensee shall reimburse OHSU for any
costs, expenses, or fees which OHSU incurs as a result of such motion or other action. Upon Licensee’s payment of all casts incurred by OHSU as a result of Licensee’s joinder motion or other action, these
actions by Licensee will not be considered a default in the performance of any material obligation under this Agreement. If Licensee elects not to defend against such declaratory judgment action, OHSU, at its option, may
do so at its own expense. In all cases, Licensee agrees to keep OHSU reasonably apprized of the status and progress of any litigation. Before Licensee commences an infringement action, Licensee shall notify OHSU
and give careful consideration to the views of OHSU in deciding whether to bring suit. 

  

	12.	DISCLAIMER OF WARRANTIES AND INDEMNIFICATION 

  

	12.01	OHSU offers no warranties other than those specified in Article 1. 

  

	12.02	OHSU does not warrant the validity of the Licensed Patent Rights and makes no representations whatsoever with regard to the scope of the Licensed Patent Rights,
or that the Licensed Patent Rights may be exploited without infringing other patents or other intellectual property rights of third parties. 

  

	12.03	OHSU MAKES NO WARRANTIES, EXPRESSED OR IMPLIED, OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF ANY SUBJECT MATTER DEFINED BY THE CLAIMS OF THE LICENSED PATENT
RIGHTS. 

  

	12.04	OHSU does not represent that it will commence legal actions against third parties infringing the Licensed Patent Rights. 

  

	12.05	 Licensee shall indemnify and hold OHSU, its directors, trustees, officers, employees, students, fellows, agents, and consultants harmless from and against all
liability, demands, damages, expenses, and losses, including but not limited to death, personal injury, illness, or property damage in connection with or arising out of a) the use by or on behalf of Licensee or sublicensees, directors, employees, or
third parties of any Licensed 

  

 - 13 - 

	 	 
Patent Rights, or b) the design, manufacture, distribution, or use of any Licensed Products, Licensed Processes or materials, or other
products or processes developed in connection with or arising out of the Licensed Patent Rights, or c) otherwise arising out of exercise of Licensed Patent Rights granted under this Agreement. Licensee at all times shall
carry insurance or self-insurance sufficient to cover its contractual obligations with respect to activities performed under this Agreement. Licensee shall provide evidence of this coverage to OHSU. 

 

	13.	TERM, TERMINATION, AND MODIFICATION OF RIGHTS 

  

	13.01	This Agreement is effective as of the effective date of the Original License Agreement and shall extend to the expiration of the last to expire of the Licensed
Patent Rights unless sooner terminated as provided in this Article 13. 

  

	13.02	In the event that Licensee is in default in the performance of any material obligations under this Agreement, and if the default has not been remedied within sixty
(60) days after the date of notice in writing of such default, OHSU may terminate this Agreement by written notice. 

  

	13.03	Licensee may, upon sixty (60) days written notice to OHSU, terminate this Agreement by doing all of the following: 

  

	 	a)	Ceasing to make, have made, use, import, sell and offer for sale any Licensed Products and/or use of Licensed Processes; 

  

	 	b)	Terminating all sublicenses, and causing all sublicensees to cease making, having made, using, importing, selling and offering for sale any Licensed Products and/or use of
Licensed Processes; and 

  

	 	c)	Paying all monies owed to OHSU under this Agreement 

  

	13.04	OHSU shall specifically have the right to terminate this Agreement if OHSU determines that: 1) Licensee is more than thirty (30) days late in paying
to OHSU any consideration due under this Agreement and Licensee does not immediately pay OHSU in full upon demand, 2) Licensee experiences a Trigger Event, or 3) Licensee breaches this
Agreement (other than a breach solely under 13.04 (1)1 and does not cure the breach within sixty (60) days after written notice of the breach. 

  

	13.05	

  

	 	a)	 OHSU shall specifically have the right to terminate or modify, at its option, this Agreement, if OHSU determines in good faith that
Licensee: 1) is not reasonably proceeding with the development and practical application (as such term is defined in 35 U.S.C. §201(f)) of Licensed Products or Licensed Processes and the Licensee can not otherwise
demonstrate to OHSU’s reasonable satisfaction that the Licensee has taken, or can be expected to take within a reasonable time, effective steps to achieve practical application of the Licensed Products or Licensed
Processes; or 2) is not keeping Licensed Products or Licensed 

  

 - 14 - 

	 	 
Processes reasonably available to the public after commercial use commences. In making this determination, OHSU will take into account the
normal course of such commercial development programs conducted with sound and reasonable business practices and judgment. Prior to invoking this right, OHSU shall give written notice to Licensee providing Licensee specific
notice of, and a sixty (60) day opportunity to respond to, OHSU’s concerns as to the previous items 1) and 2). If Licensee fails to alleviate OHSU’s concerns as to the previous items 1) and 2) or fails to initiate
corrective action to OHSU’s satisfaction, OHSU may terminate or modify this Agreement. 

  

	 	b)	Notwithstanding Paragraph 13.05(a) above, if Licensee has sublicensed its rights under this Agreement to a third party and OHSU has approved Licensee’s
execution of such sublicense pursuant to Paragraph 4.01 of this Agreement, Licensee and sublicensee shall be considered to be reasonably proceeding with development and practical application of Licensed Products and otherwise
complying with this Paragraph 13.05 while such sublicense agreement is in effect and not materially breached by sublicensee. 

  

	13.06	Within ninety (90) days of expiration or termination of this Agreement under this Article 13, a final report shall be submitted by Licensee. Any royalty payments,
including those related to patent expense, due to OHSU shall become immediately due and payable upon termination or expiration. If this Agreement is terminated under this Article 13, sublicensees may elect to convert their sublicenses
to direct licenses with OHSU pursuant to Paragraph 4.04. 

  

	13.07	Upon termination of this Agreement, in the event that a sublicensee does not convert its sublicense to a direct license with OHSU pursuant to Paragraph 4.04,
Licensee and any sublicensee shall, at OHSU’s request, return to OHSU any data provided or generated by OHSU to or for Licensee during the term of this Agreement that will facilitate the development of
the Licensed Patent Rights. Licensee will, and will cause its sublicensee who has not converted its sublicense to a direct license with OHSU to, negotiate in good faith with OHSU, or with any third party with whom
OHSU is in confidential discussions for the license of Licensed Patent Rights subsequent to the termination of this Agreement, for the sale of any such data owned or controlled by Licensee and/or its sublicensee that will
facilitate the development of the Licensed Patent Rights. 

  

	13.08	 Upon termination of this Agreement, Licensee shall cause physical inventories to be taken immediately of: (a) all completed Licensed
Products or products requiring the use of Licensed Processes on hand under the control of Licensee or any sublicensee; and (b) such Licensed Product(s) or products as are in the process of manufacture and component
parts thereof as of the date of termination of this Agreement, which inventories shall be reduced to writing. Licensee shall deliver copies of such written inventories, verified by an officer of Licensee forthwith to
OHSU. OHSU shall have 46 days after receipt of such verified inventories within which to challenge the inventory and request an audit. Upon five days written notice to Licensee, OHSU and its agents shall be given access
during business hours to the premises of Licensee or its sublicensees for 

  

 - 15 - 

	 	 
the purpose of conducting an audit. Upon the termination of this Agreement, Licensee shall, at its own expense forthwith remove, efface or
destroy all references to OHSU from all advertising or other materials used in the promotion of Licensee’s business or the business of any sublicensee and Licensee and any sublicensee shall not thereafter represent in any
manner that it has rights in or to the Licensed Patent Rights or Licensed Product(s) or products requiring the use of Licensed Process(es). 

  

	13.09	Notwithstanding the foregoing, if this Agreement terminates other than pursuant to Paragraph 13.04 1) or 2), Licensee shall have a period of six (6) months to
sell off its inventory of Licensed Product(s) or products requiring the use of Licensed Process(es) existing on the date of termination of this Agreement and shall pay royalties to OHSU with respect to such Licensed
Product(s) and products within thirty (30) days following the expiration of such six-month period (“Sell Off Right”). 

  

	13.10	Paragraphs 4.06, 6.06, 6.07, 8.01, 9.06, 12.01-12,05, 13.06-13.10, and 14.12 of this Agreement shall survive termination of this Agreement. Licensee’s
obligation to pay all monies owed accruing under this Agreement shall survive termination of this Agreement. 

  

	14.	GENERAL PROVISIONS 

  

	14.01	Neither party may waive or release any of its rights or interests in this Agreement except in writing. The failure of OHSU to assert a right hereunder or to insist
upon compliance with any term or condition of this Agreement shall not constitute a waiver of that right by OHSU or excuse a similar subsequent failure to perform any such term or condition by Licensee. 

 

	14.02	This Agreement constitutes the entire agreement between the parties relating to the subject matter of the Licensed Patent Rights, and all prior negotiations,
representations, agreements, and understandings are merged into, extinguished by, and completely expressed by this Agreement. 

  

	14.03	The provisions of this Agreement are severable, and in the event that any provision of this Agreement shall be determined to be invalid or unenforceable under any
controlling body of law, such determination shall not in any way affect the validity or enforceability of the remaining provisions of this Agreement. 

  

	14.04	If either party desires a modification to this Agreement, the parties shall, upon reasonable notice of the proposed modification by the party desiring the change, confer in
good faith to determine the desirability of such modification. No modification will be effective until a written amendment is signed by the signatories to this Agreement or their designees. 

  

	14.05	The construction, validity, performance, and effect of this Agreement shall be governed by the laws of the State of Oregon. 

  

	14.06	All notices required or permitted by this Agreement shall be given by prepaid, first class, registered or certified mail properly addressed to the other party at the address
designated on the following Signature Page, or to such other address as may be designated in writing by such other party, and shall be effective as of the date of the postmark of such notice. 

  

 - 16 - 

	14.07	This Agreement shall not be assigned by Licensee except a) to an Affiliate, b) with the prior written consent of OHSU, such consent not to be unreasonably
withheld, and to be deemed given if Licensee requests OHSU’s consent and OHSU does not respond to Licensee’s request within sixty (60) days of said request; or c) as part of a sale or transfer of
substantially the entire business of Licensee relating to operations which concern this Agreement. Licensee, shall notify OHSU within ten (10) days of any assignment of this Agreement by Licensee.

  

	14.08	Licensee agrees in its use of any OHSU-supplied materials to comply with all applicable statutes, regulations, and guidelines. 

  

	14.09	In connection with this Agreement, the parties may provide to each other certain confidential information (“Confidential Information”). Each party agree to take
customary steps to protect Confidential Information of the other party, including according such information the same policies and procedures applicable to its own confidential business information. Confidential Information will be disclosed to
agents, employees, and sublicensees of Licensee only on a “need-to-know” basis and only after such persons or companies have been informed of and obligated to maintain confidentiality. Each party will use the Confidential
Information of the other only in connection with exercising its rights under this Agreement. Confidential Information will not include information which is now or becomes part of the public domain through no fault of the receiving party, was
already known by the receiving party at the time of disclosure by the disclosing party, was independently developed by the receiving party without use of Confidential Information of the other party, was obtained from a third party not under any
confidentiality obligation with respect to such information, or was required to be disclosed by law, including the Oregon Public Records Law. 

  

	14.10	Licensee acknowledges that it is subject to and agrees to abide by the United States laws and regulations (including the Export Administration Act of 1979 and Arms Export
Control Act) controlling the export of technical data, computer software, laboratory prototypes, biological material, and other commodities. The transfer of such items may require a license from the cognizant agency of the Government or
written assurances by Licensee that it shall not export such items to certain foreign countries without prior approval of such agency. OHSU neither represents that a license is or is not required or that, if required, it shall be
issued. 

  

	14.11	Licensee agrees to mark the Licensed Products or products requiring the use of Licensed Processes or their packaging sold in the United States with all
applicable U.S. patent numbers and similarly to indicate “Patent Pending” status. All Licensed Products or products requiring the use of Licensed Processes manufactured in, shipped to, or sold in other countries shall be
marked in such a manner as to preserve OHSU patent rights in such countries. 

  

 - 17 - 

	14.12	By entering into this Agreement, OHSU does not directly or indirectly endorse any product or service provided, or to be provided, by Licensee whether directly
or indirectly related to this Agreement. Licensee shall not state or imply that this Agreement is an endorsement by OHSU, or its employees. Additionally, Licensee shall not use the names of OHSU or their
employees in any advertising, promotional, or sales literature without the prior written consent of OHSU. Either party may issue a press release regarding this Agreement provided that the contents of said press release are mutually
agreed to by the parties. 

  

	14.13	The parties agree to attempt to settle amicably any controversy or claim arising under this Agreement or a breach of this Agreement, including use of mediation.

 [SIGNATURES BEGIN ON NEXT PAGE.] 
  

 - 18 - 

 OHSU PATENT LICENSE AGREEMENT EXCLUSIVE/EQUITY 
 SIGNATURE PAGE 
  

							
	FOR OHSU:	 		 	
				
	by:	 	 /s/ Arundeep S. Pradhan
	 		 	
		 		 		 	Date May 25, 2007
	Arundeep S. Pradhan	 		 	
	Director, Technology and Research	 		 	
	Collaborations, Oregon Health & Science University	 		 	

	
	
	Mailing Address for Notices:
	
	 Technology and Research Collaborations, L335

	 Oregon Health & Science University

	 2525 S.W. First Avenue, Suite 120

	 Portland, Oregon 97201

  

	
	
	 
	Licensee

  

							
				
	by:	 	 /s/ John P. Walker
	 		 	
	 Signature of Authorized Official
	 		 	Date
			
	 John P. Walker
	 		 	
	 Printed Name
	 		 	
			
	 Chairman-Interim CEO
	 		 	
	 Title
	 		 	

  

			
	Mailing Address for Notices:	 	
		
	 601 Gateway Blvd., Suite 800
	 	
	 South San Francisco, Ca 94080
	 	

  

 - 19 - 

 APPENDIX A 
 Patent or Patent Application 
 PCT Patent Application #W0 99/49870 “Vitamin D and its Analogs in the Treatment
of Tumors and Other Hyperproliferative Disorders.” Patent applications related to the pulsatile high-dose administration of Vitamin D and analogs in tumors and other hyperproliferative disorders, including, but not limited to, as follows:

  

															
	Matter ID	  	 Country
	  	 Title
	  	 Inventor
	  	 Filing
 Date
	 	 Application
 No.
	 	Issue Date	 	 Patent
 No.

	[*]	  	[*]	  	[*]	  	[*]	  	[*]	 	[*]	 	[*]	 	[*]

  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 - 20 - 

 APPENDIX B 
 Term Sheet 

 June 12, 2001 
 TERM SHEET 
  

			
	Company	  	D-Novo Therapeutics, Inc. (the “Company”)
		
	Amount	  	$12,000,000
		
	Securities	  	Series A-1 Preferred Stock (“Series A-1 Preferred Stock”) and Series A-2 Preferred Stock (“Series A-2 Preferred Stock” and together with the Series A-1 Preferred Stock, the
“Series A Preferred”)
		
	Number of Shares	  	 4,000,000 shares of Series A-1 Preferred Stock
 4,000,000
shares of Series A-2 Preferred Stock

		
	Purchase Price	  	 Series A-1 Preferred Stock: $1.25 per share
 Series A-2
Preferred Stock: $1.75 per share

		
	Closing Date	  	July ____, 2001, or sooner for the Series A-1 Preferred Stock and upon the achievement of certain mutually agreeable milestones for the Series A-2 Preferred Stock.
		
	Participants	  	 Domain Partners V, L.P.
 DP V Associates, L.P:

Sofinnova Ventures
 ProQuest Investments
  
 See Projected Capitalization Table for Amount to be invested by each Participant
 (Exhibit A)

		
	TERMS OF SERIES A PREFERRED STOCK:	  	
		
	Conversion	  	The holders of the Series A Preferred shall have the right to convert the Series A Preferred at the option of the holder, at any time into Common Stock of the Company. The initial conversion
rate shall be on a one-to-one basis and shall be subject to adjustment.
		
	Conversion Price	  	The initial conversion price of the Series A-1 Preferred Stock will be $1.25 per share and the initial conversion price of the Series A-2 Preferred Stock will be $1.75 per
share.

			
	Automatic Conversion	  	The Series A Preferred will be automatically converted into Common Stock, at the then applicable conversion rate, upon (i) the closing of a firmly underwritten public offering of shares of
Common Stock of the Company at a price per share of not less than $4.50 per share (adjusted to reflect subsequent stock dividends, stock splits or recapitalization) and for total gross offering proceeds of not less than $30,000,000 or (ii) the
approval of the holders of at least two-thirds (2/3) of the Series A Preferred, voting together as a class.
		
	Antidilution	  	The respective conversion prices of the Series A Preferred will be .subject to adjustment to prevent dilution, on a broad-based weighted average basis, in the event that the Company issues
additional shares of Common Stock, convertible securities or warrants or grants stock options or issues other Common Stock equivalents (other than (i) 2,000,000 shares of Common Stock to officers, employees, directors, consultants or advisors of the
Company pursuant to stock option or restricted stock purchase plans or agreements as approved by the Board of Directors, (ii) securities issued in connection with research and development partnerships, licensing or collaborative arrangements,
equipment lease financing arrangements, credit agreements, debt financings, and similar transactions approved by the Board of Directors and the holders of at least two-thirds (2/3) of the Series A Preferred, voting together as a class, (iii) shares
of Common Stock issued upon conversion of or as a dividend or distribution on the Series A Preferred, and (iv) shares of Common Stock issued or issuable for consideration other than cash pursuant to a merger, consolidation, acquisition or similar
business combination (approved by the Board of Directors and the holders of at least two-thirds (2/3) of the Series A Preferred, voting together as a class) at a purchase price less than the applicable conversion price. Such antidilution protection
will be subject to a “play or pay” provision, as defined below.
		
	Dividends	  	The holders of the Series A-1 Preferred Stock and the Series A-2 Preferred Stock will be entitled to receive a noncumulative dividend in on a pari passu basis with one another and prior
and in preference to any dividend on Common Stock at the rate of 8% of the per share purchase price per annum, when, as and if declared by the Board of Directors. The Series A Preferred shall participate on a pari passu basis with the Common
Stock on an as-converted basis on all other dividends.
		
	Adjustments	  	In the event of any stock splits, stock dividends or combinations, an adjustment will be made such that the holders of Series A Preferred will hold the same relative ownership position after
such action as they had immediately prior to such action.

			
	Voting Rights	  	Each share of Series A Preferred will carry one vote per share of Common Stock then issuable upon its conversion. The Series A Preferred will vote together with the Common Stock and not as a
separate class, except as specifically provided herein or as otherwise required by law.
		
	Protective Provisions	  	Consent of the holders of at least two-thirds (2/3) of the Series A Preferred, voting together as a class, shall be required for any action which (i) results in the sale, disposal, or
encumbrance of all or substantially all of the Company’s property or business or the disposal of more than fifty percent (50%) of the voting power of the Company; (ii) adversely alters or changes the rights, preferences, privileges or
restrictions of the Series A Preferred; (iii) creates (by reclassification or otherwise) any new class or series of shares having rights, preferences or privileges senior to or on a parity with the Series A Preferred with respect to voting,
dividends or redemption or upon liquidation; (iv) increases the authorized number of shares of the Company’s capital stock, (v) pays or declares any dividends on any junior equity securities (other than in Common Stock of the Company); (vi)
would result in the taxation of holders of Series A Preferred under IRC section 305; (vii) increases or decreases the size of the Board of Directors; (viii) amends the Company’s existing stock option plan or approves any new equity incentive
plan; (ix) changes the Company’s line or lines of business; (x) redeems, repurchases or otherwise acquires any outstanding shares of the Company’s capital stock or rights to acquire capital stock (other than repurchases of Common Stock
from employees upon termination); (xi) permits the Company to incur indebtedness (other than payables in the ordinary course of business) in excess of $1,500,000 in the aggregate; (xii) causes the Company to acquire, merge or consolidate with or
into any corporation or Purchase all or substantially of the assets of any corporation, or permits any subsidiary to do so; or (xiii) amends the Company’s Certificate of Incorporation or Bylaws in any manner that would alter or change any of
the rights, preferences, privileges or restrictions of the Series A Preferred.
		
	Preference on Liquidation	  	In the event of any liquidation, dissolution or winding up of the Company, the holders of Series A-1 Preferred Stock and the Series A-2 Preferred Stock will be entitled to receive, on pari
passu basis with one another and prior to any distributions made to the holders of Common Stock or any

			
		  	other junior equity security, (a) in the case of the Series A-1 Preferred Stock, an amount equal to $1.25 per share (as adjusted for stock splits and the like) plus all declared but unpaid
dividends on such shares and (b) in the case of the Series A-2 Preferred Stock, an amount equal to $1.75 per share (as adjusted for stock splits and the like) plus all declared but unpaid dividends on such shares (collectively, the
“Preferential Amounts”). After payment of each of the respective Preferential Amounts to the holders of Series A Preferred, the holders of Series A Preferred and the Common Stock will be entitled to receive the remaining assets or property
of the Company on an as converted basis until each holder of Series A Preferred has received an aggregate of seven (7) times its respective Preferential Amount. Thereafter, any remaining assets or property of the Company shall be distributed
pro-rata among the holders of the Common Stock. In the event the assets of the Company are insufficient to pay the full Preferential Amounts to all holders of Series A Preferred, the assets of the Company shall be distributed ratably among such
holders in proportion to the product of the liquidation preference for each such share and the number of shares owned by such holder.
		
	Merger, Consolidation	  	A merger, other corporate reorganization, sale Of control, or any transaction in which all or substantially all of the assets of the Company are sold (other than a merger into a wholly owned
subsidiary) (a “Liquidating Merger”) will be treated as a liquidation for purposes of the Series A Preferred liquidation preference.
		
	Registration Rights	  	Commencing upon the earlier to occur of (a) four (4) years from -the date of the closing of the sale of the Series A-1 Preferred ‘Stock or (b) six (6) months after the Initial Public
Offering (as defined below), the holders of Registrable Securities (Common Stock issued or issuable upon conversion of the Series A Preferred) will have the right to demand two (2) registrations, each such demand being at the request of the holders
of at least twenty percent (20%) of the then outstanding Registrable Securities. Holders of at least 1,000,000 shares of such securities will also have rights to an unlimited number of piggyback registrations, subject to the right of the Company and
its underwriters to reduce the number of Registrable Securities proposed to be registered on a pro rata basis in light of market conditions. In addition, all holders will be entitled to two (2) demand registrations on Form S-3 per year, provided
such registered offerings are not less than $1,000,000. The Company will bear registration

			
		  	Expenses (exclusive of underwriting discounts and commissions) of all demand and piggyback registrations and registrations on Form S-3. The registration rights may be transferred to (i) a
transferee or assignee of all of an investor’s Registrable Securities, (ii) another holder of Registrable Securities who already possesses registration rights, (iii) a transferee or assignee acquiring 10% or more of the outstanding stock of the
Company, provided that the Company is given written notice thereof, or (iv) to a current or former affiliated limited partnership, a limited partner, general partner or other affiliate of an investor. Registration rights will terminate on the sixth
(6th) anniversary of the closing of the first firmly underwritten public offering of shares of Common Stock of the Company (the “Initial Public Offering”), or, with respect to each investor, at the time the investor is entitled to sell all
of such investor’s Company shares pursuant to Rule 144 (including Rule 144(k)). In connection with the grant of registration rights, the investors will agree not to sell their Company shares for a specified period (not to exceed 180 days)
following the effective date of the Initial Public Offering.
		
	Right of First Offer	  	In connection with any subsequent offering of equity securities by the Company, each investor will have a right of first offer to purchase its respective pro rata share of offerings of new
securities of the Company (other than (i) 2,000,000. shares of Common Stock issued to certain officers, directors, employees, consultants and advisors of the Company .pursuant to stock option or restricted stock purchase plans :or agreements as
approved by the Board of Directors, (ii) securities issued in connection with research and development partnerships, licensing or collaborative arrangements, equipment lease financing arrangements, credit agreements, debt financings, and similar
transactions approved by the Board of Directors and the holders of at least two-thirds (2/3) of the Series A Preferred, voting together as a class, (iii) shares of Common. Stock issued upon conversion of the Series A Preferred, (iv) shares of Common
Stock issued in connection with any stock split, stock dividend or recapitalization; and (v) securities issued or issuable for consideration other than cash pursuant to a merger, consolidation, acquisition or similar business combination approved by
the Board of Directors and the holders of at least two-thirds (2/3) of the Series A Preferred, voting together as a class. The right of first offer will terminate on the closing of, and will not apply to, the first firmly underwritten public
offering of shares of Common Stock of the Company that

			
		  	results in conversion of the Series A Preferred into Common Stock in accordance with the Company’s Certificate of Incorporation as in effect at the time of such offering (the
“Qualified Public Offering”) or upon an acquisition, merger or consolidation of the Company in which the holders of voting stock immediately prior to such transaction own, immediately after such transaction, less than fifty percent (50%)
of the voting stock of the surviving entity in such transaction (a “Change in Control”).
		
	Restrictions on Sales	  	The Company (or its assignee) will have a right of first refusal (and the investors shall have a right of second refusal) on all transfers of Common Stock, except to family trusts and in certain
other limited circumstances. This right of first refusal will terminate upon the Initial Public Offering. Holders of more than 250,000 ‘shares of Series A Preferred (including venture capital funds affiliated with any such holder) will have the
right of co-sale on a pro rata basis with respect to sales of the Company’s stock by the Company’s founder (the “Founder”). This right of second refusal and co-sale will terminate upon, and will not apply to, a Qualified Public
Offering or a Change of Control.
		
	Play or Pay	  	Unless the holders of at least two-thirds (2/3) of the Series A Preferred deem otherwise or the Board of Directors requests a different investment commitment, in the event a holder of the Series
A Preferred does not purchase its pro rata share of future issuances of the Company’s .capital stock offered to such holder pursuant to’ the right of first offer, the holder of such shares (and any transferee thereof) waives any and all
future antidilution adjustments with respect to the conversion price of such holder’s shares of Series A Preferred and waives all rights of first offer of future offerings of new securities of the Company.
		
	Information Requirements	  	Each investor or its assignee or transferee will receive annual audited financial statements. So long as an investor (or a venture capital fund affiliated with such investor) or its assignee or
transferee holds at least 250,000 shares of Series A Preferred, the Company will provide to such investor monthly unaudited financial statements, and 60 days prior to the close of each .fiscal year, a comprehensive operating budget forecasting the
Company’s revenues, expenses and cash position on a month-to-month basis for the upcoming fiscal year. The foregoing reporting obligations will terminate upon the Initial Public Offering or a Change of Control. Additionally, those venture
investors so requesting will be provided with a “Management Rights” letter which is in a form that is compliant with current Department of Labor regulations.

			
	Purchase Agreement	  	The investments in Series A Preferred shall be made pursuant to Stock Purchase Agreements reasonably acceptable to the Company and the investors, which agreements shall contain, among other
things, appropriate representations and warranties of the Company, covenants of the Company reflecting the provisions set forth herein and appropriate conditions of closing including an opinion of counsel for the Company.
		
	EMPLOYEE MATTERS:	  	
		
	Stock Vesting	  	Common Stock to be issued to officers, directors, employees, consultants and advisors will be subject to vesting over a four-year period with the initial vesting occurring on the first
anniversary of the date of grant. At the option of the Board of Directors, agreements may provide that Founder shall continue to vest so long as he continues to provide services to the Company as an employee, consultant, advisor or as a member of
the Board of Directors. At the option of the Board of Directors, agreements may provide that vesting shall accelerate in the event of a change of control or initial public offering. A repurchase option will provide that upon termination of the
employment of the stockholder, with or without cause, the Company has the option to repurchase at cost any unvested shares held by such stockholder. All shares issued to non-employee directors shall be issued under a plan which is applicable to ALL
non-employee directors.
		
	Proprietary Information Agreements	  	Each employee, consultant and adviser to the Company shall have entered into appropriate agreements regarding proprietary information, confidentiality and assignment of
inventions.
		
	Indemnification Agreements	  	The Company shall enter into the Sofinnova form of Indemnification Agreement with each of the investors and their affiliated funds.
		
	OTHER MATTERS:	  	
		
	Conditions to Closing	  	The sale of the Series A-1 Preferred Stock will close as soon as the following conditions have been met:
		
		  	 1.      Completion of legal documentation satisfactory to the prospective investors.

			
		  	 2.      Satisfactory conclusion of intellectual property review by legal
counsel acceptable to all parties and completion of a written summary by said legal counsel.
  
 3.      Satisfactory completion of due diligence by the investors.
  
 The sale of the Series A-2 Preferred Stock will close as soon as the following conditions have been
met:
  
 1.      A
permanent Chief Executive Officer, Vice President of Regulatory, and Chief Medical Officer all commence employment.
  
 2.      The company expands its patent estate by filing patents to protect novel formulations of
calcitriol .
  
 3.      The Company develops and the Board of Directors unanimously approves a clinical development plan for at least three phase II, FDA approved cancer programs including prostate cancer.
  
 Any of the A-2 conditions can be waived by the unanimous approval of the board of
directors.

		
	Participation in Series B Preferred Stock Financing	  	 Each investor, or their affiliates, shall agree to invest a minimum of the amount invested by such investor in the Company’s Series A Preferred
financing in the Company’s Series B Preferred Stock (the “Series B Preferred”) financing, provided the following conditions are satisfied:
  
 1.      New investors shall invest between $12,000,000 and $18,000,000 in the Series B Preferred
financing.
  
 2.      The Series B Preferred financing shall be led with a minimum of a $10,000,000 investment from a single, nationally recognized, investment banking or venture capital firm that is not an affiliate of any
existing stockholder of the Company.
  
 3.      Statistically significant (P<0.10), clinically meaningful efficacy shall have been achieved in a Phase II trial in the United States under a Company-sponsored, FDA approved IND in one cancer
indication which was approved by the Company’s Clinical Advisory Board

			
		  	 4.      The Series B Preferred is sold at a price of $3.00 or less per
share.
  
 5.      The Company shall in license technology for the use of calcitriol analogues in the treatment of cancer.
  
 — OR —
  
 1.      The Company shall in license a product that is in the market or that has positive Phase III
clinical data.
  
 Any of the foregoing conditions can be waived by a unanimous vote of
the holders of the Series A Preferred. The terms of the Series B Preferred financing shall be agreed upon by the Company, the new lead investor and the holders of the Series A Preferred.

		
	Finders	  	The Company and the investors shall each indemnify the other for any finders’ fees for which either is responsible.
		
	Legal Fees and Expenses	  	The Company and the investors will each bear their respective fees and expenses associated with the transaction contemplated by this Term Sheet, except that the Company shall pay the reasonable
fees and expenses of one special counsel to the investors, not to exceed $35,000. In addition, the Company will reimburse the investors for reasonable, actual fees and expenses incurred as part of the intellectual property review, not to exceed
$15,000.
		
	Board of Directors	  	The initial Board of Directors will consist of five individuals including James C. Blair, Eckard Weber, M.D. Jim Healy, Jay Moorin and one vacancy. At each subsequent election of directors, (i)
the holders of Common stock, voting separately as a class, will be entitled to elect two directors, (ii) Domain Partners V, L.P., Sofinnova Ventures and ProQuest Investments shall each be entitled to elect one director, so long as they each hold at
least fifty percent (50%) of their respective original investment in the Company, and (iii) the remaining directors will ‘be elected by the holders of Common Stock and the holders of Series A Preferred, voting together as a single class. After
the closing of the sale of the Series A-1 Preferred Stock, the size of the Board may be increased to seven members to include one additional designee of the Common Stock and one independent director elected by’ the holders of Common Stock and
the holders of Series A Preferred, voting together as a single class.

			
		  	The Company will reimburse reasonable costs incurred by non-employee directors in attending Board meetings, or otherwise supporting Company activities. All shares issued to non-employee
directors shall be issued under a plan which is applicable to all non-employee directors.
		
	Management Rights	  	The Company and Domain shall enter into Domain’s standard form of Management Rights Letter. See Exhibit B.
		
	Capitalization	  	The anticipated pro forma capitalization of the Company as of each of the Series A closings is set forth on Exhibit A.
		
	Non-Binding	  	The term sheet is not an offer, binding commitment, or contract. No obligations shall exist unless and until all parties have executed mutually acceptable definitive documents.

 [Signature Page Follows] 

					
	Company:	 		 	Investors:
			
	  	 		 	  
	Signature
                                        
                                Date	 		 	Signature
                                        
                                Date
			
	  	 		 	  
	Printed Name	 		 	Printed Name
			
	  	 		 	  
	Position	 		 	Position

 APPENDIX C 
 Investment Representation Letter 

 D-Novo Therapeutics, Inc. 
 [address] 
 Gentlemen: 
 In connection with the
undersigned’s proposed acquisition of Eight Hundred Thousand (800;000) shares of the Common Stock (the “Shares”) of D-Novo Therapeutics; Inc., a Delaware corporation (the “Company”), in exchange for the grant by the
undersigned to the Company of certain exclusive license rights, the undersigned hereby represents and warrants to the Company as follows: 
 1. The
undersigned is acquiring the Shares for investment purposes only, for the undersigned’s own account and not with a view to or for sale in connection with any distribution of the Shares. 
 2. The undersigned, by reason of its business or financial experience, has the capacity to protect its own interests in connection with its acquisition of the Shares.

 3. The undersigned is aware that no market exists or -may ever exist for the resale of the Shares. The undersigned also is aware of any and all
restrictions imposed by the Company on the further distribution of the Shares, including without limitation the fact that the certificates representing the Shares will have affixed thereto a legend stating that the Shares are not registered under
the Securities Act of 1933, as amended (the “Act”), and those legends which are required by the terms of the Stock Restriction Agreement between the Company and the undersigned. 
 4. The undersigned understands that an investment in the Shares is speculative and that, as the Shares have not been registered under the Act and no market exists or may
ever exist for the resale of the Shares, the undersigned may be required to hold onto the Shares for an indefinite period of time and may lose its entire investment with respect thereto. 
 5. The undersigned also understands that the Shares are being issued to it without registration under federal securities laws and without registration or qualification under applicable state securities laws based on
the truth and accuracy of the representations set forth herein. In that regard, the undersigned acknowledges that the Company may be relying on the exemption from the qualification requirements under California law provided by Section 25102(f)
under the Corporate Securities Law of 1968 and the exemption from the registration requirements under Oregon law provided by Section 59.035(12)(a) of the Oregon Revised Statutes, which exemptions depend in part on the truth and accuracy of the
representations set forth herein. 
 Very truly yours, 

			
	THE OREGON HEALTH & SCIENCE UNIVERSITY
		
	By:	 	 
		
	Title:	 	 

 APPENDIX D 
 Stock Restriction Agreement 

 D-NOVO THERAPEUTICS, INC. 
 STOCK RESTRICTION AGREEMENT 
 THIS STOCK RESTRICTION AGREEMENT (the “Agreement”) is made
and entered into as of this ___ of ________, 2001, between D-NOVO THERAPEUTICS, INC., a Delaware corporation (the “Company”), and OREGON HEALTH & SCIENCE UNIVERSITY (“Stockholder”). 
 R E C I T A L S: 
 A. Pursuant to the
terms of that certain License Agreement dated as of the ‘date hereof by and between the Company and the Stockholder (the “License Agreement”), the Stockholder will be issued shares of the Common Stock of the Company (the
“Shares”) in exchange for certain exclusive license rights. The term “Shares” refers to all such shares issued to the Stockholder and to all securities received in addition thereto or -in replacement thereof, pursuant to or in
consequence of any stock dividend, stock split, recapitalization, merger, reorganization, exchange of shares or other similar event. 
 B. In
order to provide assurance to certain holders (collectively, the “Investors”) of the Preferred Stock of the Company (the “Preferred Shares”) and thereby to assist in future equity financings of the Company, Stockholder is willing
to enter into this Agreement for the benefit of the Company, the Investors and any other person or entity who holds stock of the Company from time to time. 
 THE PARTIES AGREE AS FOLLOWS: 
 1. Company’s Right of First Refusal. 
 1.1 General. Before any Shares may be sold or otherwise transferred, the Company or its assignee(s) shall ‘have rights of
first refusal to purchase the ‘shares on the terms and conditions set forth in this Section (the “Rights of First Refusal”). The right of the Company to purchase any such securities may, in each instance, be assignable in whole or in
part to any person or entity designated by the Company. 
 1.2 Notice of Proposed Transfer. The Stockholder shall
deliver to the Company a written notice- (the “Notice”) stating: (i) the Stockholder’s bona fide intention to sell ‘or otherwise transfer such securities (the “Offered Shares”); (ii) the name of each proposed
purchaser or other transferee (“Proposed Transferee”); (iii) the number of Offered Shares to be transferred to each Proposed Transferee; and (iv) the bona fide cash price or other consideration for which the Stockholder proposes
to transfer the Offered Shares (the “Offered Price”), and the Stockholder shall offer the Offered Shares at the Offered Price to the Company or its assignee(s). 
 1.3 Exercise of Right of First Refusal. At any time within ten (10) days after receipt of the Notice, the Company and/or its
assignee(s) may, by giving written notice to the Stockholder, elect to purchase all of the Offered Shares at the purchase price determined in accordance with Section 1.4 below. 

 1.4 Purchase Price. The purchase price (“Purchase Price”) for the
Offered Shares purchased by the Company or its assignee(s) under this Section 1 shall be the Offered Price. If the Offered Price includes consideration other than cash, the cash equivalent value of the non-cash consideration shall be determined
by the Board of Directors of the Company in good faith. 
 1.5 Payment. Payment of the Purchase Price shall be made, at
the option of the of or its assignee(s), in cash (by check or wire transfer), by cancellation of all or a portion of any outstanding indebtedness of the Stockholder to the Company (or, in the case of repurchase by an assignee, to the assignee), or
by any combination thereof within forty (40) days after receipt of the Notice or in the manner and at the times set forth in the Notice. The sale shall constitute a representation and warranty by the Stockholder that the Offered Shares being
sold are free’ and clear of all liens, claims and encumbrances. 
 1.6 Stockholder’s Right to Transfer. If
all of the Offered Shares proposed in the Notice to be transferred to a given Proposed Transferee are not purchased by the Company or its assignee(s), as provided in this Section 1, then none of the Offered Shares shall be purchased under
this’ Section 1, and the Stockholder may ,sell or otherwise transfer the Offered Shares to the Proposed Transferee at the Offered Price or at a higher price, .provided that (a) such sale ‘or other transfer (1) is consummated
within one hundred and eighty (180) days after the date of the Notice, (ii) is in accordance with all the terms of this Agreement and all other agreements between the Stockholder and the Company, and (iii) is effected in accordance
with any applicable securities laws, and (b) the Proposed Transferee agrees in writing that the provisions of this Agreement shall continue to apply to the Offered Shares in the hands of the Proposed Transferee. If the Offered Shares described
in the Notice are not transferred to the Proposed Transferee within such’ period, a new Notice shall be given to the Company; and the Company or its assignees shall again be offered the Rights of First Refusal before any Offered Shares’
held by the Stockholder may be sold or otherwise transferred. 
 1.7 Termination of Rights of First Refusal. The Rights
of First Refusal under this Section 1 shall not apply to and shall terminate immediately before the closing of the Company’s initial public offering of Common Stock with net proceeds to the Company of no less than $20,000,000 and a per
share price of no less than $3.75 (as adjusted for combinations, stock dividends or splits occurring after the date hereof) pursuant to a registration statement filed with and declared effective by the Securities and Exchange Commission under the
Securities Act of 1933, as amended (the “Act”), and the Rights of First Refusal under this Section 1 shall be reinstated if there is no closing. 
 1.8 Limitations to Rights. Without regard and not subject to the provisions of this Section 1, Stockholder may sell or
otherwise assign Shares to any affiliate of Stockholder or any employee or former employee of Stockholder who is or was involved in Stockholder’s research programs relating to Vitamin D and its analogs in oncology and other disease therapies
that gave rise to the inventions that are the subject of the License Agreement, provided that each such transferee or assignee, prior to the completion of the sale, transfer, or assignment, shall have executed documents assuming the obligations of
the Stockholder under this Agreement with respect to the transferred securities. 

 2. Market Standoff. The Stockholder hereby agrees that if so: requested by the Company or any
representative of the underwriters in connection with any registration of .the offering of any securities of the Company under the Act, the Stockholder shall not sell or otherwise transfer .any Shares for a period of one hundred eighty
(180) days following the effective date of a registration statement filed under the Act; provided, however, that such restriction shall apply only to the first two registration statements of the Company to become effective under the Act which
include securities to be sold on behalf of the Company to the public in an underwritten public offering under the Act. The Company may impose, stop-transfer instructions in order to enforce the foregoing restrictions. 
 3. Stock Certificate Restrictive Legends. Stock certificates evidencing Shares may bear such restrictive legends as the Company and the
Company’s counsel deem necessary or advisable under applicable law or pursuant to this Agreement, including, without limitation, the following legends: 
 “THE SECURITIES REPRESENTED HEREBY ARE SUBJECT TO A RIGHT OF FIRST REFUSAL BY THE COMPANY PURSUANT TO THE PROVISION OF A STOCK
RESTRICTION AGREEMENT BETWEEN THE COMPANY AND THE ORIGINAL PURCHASER OF SUCH SECURITIES, AND MAY NOT BE SOLD OR OTHERWISE TRANSFERRED EXCEPT IN COMPLIANCE IN TERMS WITH’ SUCH AGREEMENT.” 
 “THE SECURITIES REPRESENTED HEREBY ARE SUBJECT TO RESTRICTIONS ON TRANSFER FOR A PERIOD OF 180 DAYS FOLLOWING THE EFFECTIVE DATE OF A
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED, FOR AN OFFERING OF THE COMPANY’S SECURITIES AS MORE FULLY PROVIDED IN A STOCK RESTRICTION AGREEMENT BETWEEN THE COMPANY AND THE ORIGINAL PURCHASER OF SUCH SECURITIES, A COPY
OF WHICH AGREEMENT IS ON FILE WITH THE COMPANY.” 
 4. Binding Effect. Subject to the limitations set forth in this Agreement,
this Agreement shall be binding upon, and inure to the benefit of, the executors, administrators, heirs, legal representatives, successors, and assigns of the parties hereto. 
 5. Damages. The Stockholder shall be liable to the Company for all costs and damages, including incidental and consequential damages, resulting
from a disposition of Shares which is not in conformity with the provisions of this Agreement. 

 6. GOVERNING LAW. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH
THE LAWS OF THE STATE OF CALIFORNIA APPLICABLE TO CONTRACTS ENTERED INTO AND WHOLLY TO BE PERFORMED WITHIN THE STATE OF CALIFORNIA BY CALIFORNIA RESIDENTS. THE PARTIES AGREE THAT THE EXCLUSIVE JURISDICTION AND VENUE OF ANY ACTION WITH RESPECT TO
THIS AGREEMENT SHALL BE IN THE SUPERIOR COURT OF CALIFORNIA FOR THE COUNTY OF ORANGE OR THE UNITED STATES DISTRICT -COURT FOR THE CENTRAL DISTRICT OF CALIFORNIA, AND EACH OF THE PARTIES HEREBY SUBMITS ITSELF TO THE EXCLUSIVE JURISDICTION AND VENUE
OF SUCH COURTS FOR THE PURPOSE OF SUCH ACTION. THE PARTIES AGREE THAT SERVICE OF PROCESS IN ANY SUCH ACTION MAY BE EFFECTED BY DELIVERY OF THE SUMMONS TO THE PARTIES IN THE MANNER PROVIDED FOR DELIVERY OF NOTICES SET FORTH IN SECTION 7.

 7. Notices. All notices and other communications under this Agreement shall be in writing. Unless and until Stockholder is
notified in writing to the contrary, all notices, communications and documents directed to the Company and related to the Agreement, if not delivered by hand, shall be mailed, addressed as follows: 
 D-NOVO THERAPEUTICS, INC. 
 [address]

 Unless and until the Company is notified in writing to the contrary, all notices, communications and documents intended for Stockholder and related to
this Agreement, if not delivered by hand, shall be mailed to Stockholder’s last known address as shown on the Company’s books. Notices and communications shall be mailed by registered or certified mail, return receipt requested, postage
prepaid. All notices related to this Agreement shall be deemed received upon :delivery or, if mailed, within five (5) days after mailing in accordance with this Section 7. 
 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first above written. 
  

			
	D-NOVO THERAPEUTICS, INC.
		
	By:	 	 
		 	Eckard Weber, M.D., President
		 	Chief Executive Officer

 Stockholder hereby accepts and agrees to be bound by all of the terms and conditions of this
Agreement. 

			
	THE OREGON HEALTH & SCIENCE UNIVERSITY
		
	By:	 	 
		
	Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00130-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00130-of-00352.parquet"}]]